<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Wavefront excimer laser refractive surgery for adults with refractive errors - Li, S-M - 2020 | Cochrane Library</title> <meta content="Wavefront excimer laser refractive surgery for adults with refractive errors - Li, S-M - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012687.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Wavefront excimer laser refractive surgery for adults with refractive errors - Li, S-M - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012687.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012687.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Wavefront excimer laser refractive surgery for adults with refractive errors" name="citation_title"/> <meta content="Shi-Ming Li" name="citation_author"/> <meta content="Capital Medical University" name="citation_author_institution"/> <meta content="lishiming81@163.com" name="citation_author_email"/> <meta content="Meng-Tian Kang" name="citation_author"/> <meta content="Capital Medical University" name="citation_author_institution"/> <meta content="Ning-Li Wang" name="citation_author"/> <meta content="Capital Medical University" name="citation_author_institution"/> <meta content="Samuel A Abariga" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD012687.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012687.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012687.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012687.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Astigmatism [surgery]; Corneal Wavefront Aberration [*surgery]; Hyperopia [surgery]; Keratectomy, Subepithelial, Laser-Assisted [adverse effects, *methods]; Keratomileusis, Laser In Situ [adverse effects, *methods]; Lasers, Excimer [*therapeutic use]; Myopia [surgery]; Photorefractive Keratectomy [adverse effects, *methods]; Randomized Controlled Trials as Topic; Treatment Outcome; Visual Acuity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012687.pub2&amp;doi=10.1002/14651858.CD012687.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012687\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012687\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012687.pub2",title:"Wavefront excimer laser refractive surgery for adults with refractive errors",firstPublishedDate:"Dec 18, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012687.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012687.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012687.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012687.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012687.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012687.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012687.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012687.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2501 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012687.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/appendices#CD012687-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/table_n/CD012687StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/table_n/CD012687StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Wavefront excimer laser refractive surgery for adults with refractive errors</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#CD012687-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Shi-Ming Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#CD012687-cr-0005">Meng-Tian Kang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#CD012687-cr-0006">Ning-Li Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information#CD012687-cr-0007">Samuel A Abariga</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information/en#CD012687-sec-0110">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012687.pub2">https://doi.org/10.1002/14651858.CD012687.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012687-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012687-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012687-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012687-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012687-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012687-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012687-abs-0001" lang="en"> <section id="CD012687-sec-0001"> <h3 class="title" id="CD012687-sec-0001">Background</h3> <p>Refractive errors (conditions in which the eye fails to focus objects accurately on the retina due to defects in the refractive system), are the most common cause of visual impairment. Myopia, hyperopia, and astigmatism are low‐order aberrations, usually corrected with spectacles, contact lenses, or conventional refractive surgery. Higher‐order aberrations (HOAs) can be quantified with wavefront aberration instruments and corrected using wavefront‐guided or wavefront‐optimized laser surgery. Wavefront‐guided ablations are based on preoperative measurements of HOAs; wavefront‐optimized ablations are designed to minimize induction of new HOAs while preserving naturally occurring aberrations. Two wavefront procedures are expected to produce better visual acuity than conventional procedures. </p> </section> <section id="CD012687-sec-0002"> <h3 class="title" id="CD012687-sec-0002">Objectives</h3> <p>The primary objective was to compare effectiveness and safety of wavefront procedures, laser‐assisted in‐situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) or laser epithelial keratomileusis (LASEK) versus corresponding conventional procedures, for correcting refractive errors in adults for postoperative uncorrected visual acuity, residual refractive errors, and residual HOAs. The secondary objective was to compare two wavefront procedures. </p> </section> <section id="CD012687-sec-0003"> <h3 class="title" id="CD012687-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, which contains the Cochrane Eyes and Vision Trials Register; 2019, Issue 8); Ovid MEDLINE; Ovid Embase; Latin American and Caribbean Health Sciences (LILACS); the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 6 August 2019. We imposed no restrictions by language or year of publication. We used the Science Citation Index (September 2013) and searched the reference lists of included trials to identify additional relevant trials. </p> </section> <section id="CD012687-sec-0004"> <h3 class="title" id="CD012687-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing either wavefront modified with conventional refractive surgery or wavefront‐optimized with wavefront‐guided refractive surgery in participants aged ⪰ 18 years with refractive errors. </p> </section> <section id="CD012687-sec-0005"> <h3 class="title" id="CD012687-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology.</p> </section> <section id="CD012687-sec-0006"> <h3 class="title" id="CD012687-sec-0006">Main results</h3> <p>We identified 33 RCTs conducted in Asia, Europe and United States, totaling 1499 participants (2797 eyes). Participants had refractive errors ranging from high myopia to low hyperopia. Studies reported at least one of the following review‐specific outcomes based on proportions of eyes: with uncorrected visual acuity (UCVA) of 20/20 or better, without loss of one or more lines of best spectacle‐corrected visual acuity (BSCVA), within ± 0.50 diopters (D) of target refraction, with HOAs and adverse events. </p> <p><b>Study characteristics and risk of bias</b> </p> <p>Participants were mostly women, mean age 29 and 53 years, and without previous refractive surgery, ocular pathology or systemic comorbidity. We could not judge risks of bias for most domains of most studies. Most studies in which both eyes of a participant were analyzed failed to account for correlations between two eyes in the analysis and reporting of outcomes. </p> <p><b>Findings</b> </p> <p>For the primary comparison between wavefront (PRK or LASIK or LASEK) and corresponding conventional procedures<b>,</b> 12‐month outcome data were available from only one study of PRK with 70 participants. No evidence of more favorable outcomes of wavefront PRK on proportion of eyes: with UCVA of 20/20 or better (risk ratio [RR] 1.03, 95% confidence interval (CI) 0.86 to 1.24); without loss of one or more lines of BSCVA (RR 0.94, 95% CI 0.81 to 1.09); within ± 0.5 D of target refraction (RR 1.03, 95% CI 0.86 to 1.24); and mean spherical equivalent (mean difference [MD] 0.04, 95% CI −0.11 to 0.18). The evidence for each effect estimate was of low certainty. No study reported HOAs at 12 months. </p> <p>At six months, the findings of two to eight studies showed that overall effect estimates and estimates by subgroup of PRK or LASIK or LASEK were consistent with those for PRK at 12 month, and suggest no difference in all outcomes. The certainty of evidence for each outcome was low. </p> <p>For the comparison between wavefront‐optimized and wavefront‐guided procedures at 12 months, the overall effect estimates for proportion of eyes: with UCVA of 20/20 or better (RR 1.00, 95% CI 0.99 to 1.02; 5 studies, 618 participants); without loss of one or more lines of BSCVA (RR 0.99, 95% CI 0.96 to 1.02; I<sup>2</sup> = 0%; 5 studies, 622 participants); within ± 0.5 diopters of target refraction (RR 1.02, 95% CI 0.95 to 1.09; I<sup>2</sup> = 33%; 4 studies, 480 participants) and mean HOAs (MD 0.03, 95% CI −0.01 to 0.07; I<sup>2</sup> = 41%; 5 studies, 622 participants) showed no evidence of a difference between the two groups. Owing to substantial heterogeneity, we did not calculate an overall effect estimate for mean spherical equivalent at 12 months, but point estimates consistently suggested no difference between wavefront‐optimized PRK versus wavefront‐guided PRK. However, wavefront‐optimized LASIK compared with wavefront‐guided LASIK may improve mean spherical equivalent (MD −0.14 D, 95% CI −0.19 to −0.09; 4 studies, 472 participants). All effect estimates were of low certainty of evidence. </p> <p>At six months, the results were consistent with those at 12 months based on two to six studies. The findings suggest no difference between two wavefront procedures for any of the outcomes assessed, except for the subgroup of wavefront‐optimized LASIK which showed probable improvement in mean spherical equivalent (MD −0.12 D, 95% CI −0.19 to −0.05; I<sup>2</sup> = 0%; 3 studies, 280 participants; low certainty of evidence) relative to wavefront‐guided LASIK.<br/>We found a single study comparing wavefront‐guided LASIK versus wavefront‐guided PRK at six and 12 months. At both time points, effect estimates consistently supported no difference between two procedures. The certain of evidence was very low for all estimates. </p> <p><b>Adverse events</b> </p> <p>Significant visual loss or optical side effects that were reported were similar between groups. </p> </section> <section id="CD012687-sec-0007"> <h3 class="title" id="CD012687-sec-0007">Authors' conclusions</h3> <p>This review suggests that at 12 months and six months postoperatively, there was no important difference between wavefront versus conventional refractive surgery or between wavefront‐optimized versus wavefront‐guided surgery in the clinical outcomes analyzed. The low certainty of the cumulative evidence reported to date suggests that further randomized comparisons of these surgical approaches would provide more precise estimates of effects but are unlikely to modify our conclusions. Future trials may elect to focus on participant‐reported outcomes such as satisfaction with vision before and after surgery and effects of remaining visual aberrations, in addition to contrast sensitivity and clinical outcomes analyzed in this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012687-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012687-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012687-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012687-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012687-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012687-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012687-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012687-abs-0002" lang="en"> <h3>What are the benefits and risks of wave‐front excimer laser refractive surgery for common eye disorders? </h3> <p><b>Why is this question important?</b><br/>Refractive errors are the most common cause of poor vision worldwide. People with refractive errors have trouble focusing, because of irregularities in the shape of their eyes. This causes: </p> <p>‐ Nearsightedness (myopia), which makes far‐away objects look blurry;<br/>‐ Farsightedness (hyperopia), which makes nearby objects look blurry; and<br/>‐ Astigmatism, which can make far‐away and nearby objects look blurry or distorted. </p> <p>Refractive errors can be corrected with glasses or contact lenses, or treated with surgery. Conventionally, surgeons use a computer‐controlled laser that emits ultraviolet light (excimer laser refractive surgery) to correct irregularities. Newer surgical procedures use three‐dimensional imaging technology to identify irregularities (wave‐front modified techniques); this allows the correction of much smaller irregularities than the conventional procedure. </p> <p>We reviewed the evidence from research studies to compare the benefits and risks of:</p> <p>‐ conventional excimer laser refractive surgery versus wavefront‐modified techniques; and<br/>‐ different wavefront‐modified techniques. </p> <p><b>How did we identify and evaluate the evidence?</b><br/>First, we searched for randomized controlled studies (clinical studies where people are randomly put into one of two or more treatment groups), because these studies provide the most robust evidence about the effects of a treatment. We then compared the results, and summarized the evidence from all the studies. Finally, we rated our confidence in the evidence, based on factors such as study methods and sizes, and the consistency of findings across studies. </p> <p><b>What did we find?</b><br/>We found 33 studies that involved a total of 1499 people aged 18 years or older. These studies were conducted in Asia, Europe and the USA, and followed people for between one month and one year. Most people in the studies were women, and most people were near‐sighted. </p> <p>Twelve studies reported their source of funding: two studies were funded by the US government, three studies were industry‐funded and seven studies did not receive any specific funding. </p> <p>Few studies provided information about the main effects that interested us:</p> <p>‐ improvement in vision one year after surgery; and<br/>‐ the occurrence of unwanted (adverse) effects such as significant vision loss, halos (seeing bright circles around light sources) or glare (discomfort caused by intense light). </p> <p>We have little to very little confidence in the evidence from the studies we found, mainly because the studies: </p> <p>‐ produced imprecise and inconsistent results; and<br/>‐ were designed or conducted in ways that could introduce error into their results. </p> <p><i>Conventional excimer laser refractive surgery versus wavefront‐modified techniques</i> </p> <p>In procedures where the surgeon removes the outer layer of the front of the eye to access the treatment area (photorefractive keratectomy, PRK), there may be little to no difference between conventional and wavefront‐modified techniques in vision improvement one year after surgery (one study). </p> <p>No studies investigated conventional surgery versus wavefront‐modified techniques in procedures where the surgeon creates a small flap in the front of the eye to access the treatment area (laser‐assisted in‐situ keratomileusis, LASIK). </p> <p><i>Comparisons between different wavefront‐modified techniques</i> </p> <p>There may be little to no difference between wavefront‐optimized and wavefront‐guided procedures (two different types of wavefront‐modified technique) in vision improvement one year after surgery (six studies). </p> <p>Our confidence in the evidence is too low to determine whether there is any difference in effect between wavefront‐guided PRK and wavefront‐guided LASIK (one study). </p> <p><i>Adverse effects</i> </p> <p>Fewer studies that reported information on unwanted effects suggest that there may be little or no differences between the procedures that were compared in terms of unwanted effects. </p> <p><b>What does this mean?</b><br/>There may be little to no difference in improvement of vision between: </p> <p>‐ conventional excimer laser refractive surgery and wavefront‐modified techniques when using PRK;<br/>‐ wavefront‐optimized and wavefront‐guided procedures. </p> <p>We do not know which procedures are associated with fewer unwanted effects, because of limited evidence. </p> <p>More, large and well‐conducted studies are needed to improve the evidence and provide information about unwanted effects. </p> <p><b>How‐up‐to date is this review?</b> <br/>The evidence in this Cochrane Review is current to August 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012687-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012687-sec-0094"></div> <h3 class="title" id="CD012687-sec-0095">Implications for practice</h3> <section id="CD012687-sec-0095"> <p>Our findings indicate that wavefront ablations therapy in refractive surgery had no clear advantage over conventional ablation procedure in terms of traditional outcome measures among refractive surgery candidates who have higher‐order aberrations (HOAs) in the normal range. The rationale for these procedures should be reconsidered. If wavefront ablation in refractive surgery is more expensive than conventional ablation, the additional cost is unjustified for most candidates, given the lack of evidence for their effectiveness over conventional procedures. For refractive surgery candidates with high pre‐existing HOAs, wavefront ablations may be a worthwhile option. For those candidates with very high myopia (&lt; −9.0 D) or moderate to high hyperopia (&gt; +2.0 D), wavefront ablation refractive surgery should be considered carefully, because the trials included in this review did not enrol participants with refractive errors in those ranges. </p> </section> <h3 class="title" id="CD012687-sec-0096">Implications for research</h3> <section id="CD012687-sec-0096"> <p>The findings in this review indicate some points for further research on this issue. First, we suggest a re‐evaluation of the refractive surgery approach among people with high pre‐existing HOAs. Although some studies have used a value of 0.3 μm to screen the participants with high HOAs, more research is needed to determine whether this threshold is reasonable. The interaction among different patterns of HOAs should also be considered for wavefront ablation refractive surgery. Second, the use of more specific outcomes related to HOAs or task‐related outcomes such as reading or driving to assess any changes in these outcomes is recommended. Changes in HOAs may be better assessed using lower contrast as opposed to the usual 100% contrast used for visual acuity assessment. Third, larger randomized controlled trials (RCTs) with longer periods of follow‐up should be designed and conducted to provide data required to detect or rule out clinically meaningful differences over time. Such trials should also consider accounting for correlation between eyes when paired‐eye designs are used. Restoration of a normal tear film and ocular surface may take a year or longer. It may be helpful to include some outcomes on tear film in future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012687-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012687-sec-0008"></div> <div class="table" id="CD012687-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Wavefront procedures compared to conventional procedures for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront procedures compared to conventional procedures for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront procedures<br/><b>Comparison:</b> Conventional procedures </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with conventional procedure</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ Procedure: PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 100<br/>(74 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.86 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ Procedure: LASIK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There are no data on LASIK for this outcome at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(5 to 6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/>(0.81 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 100<br/>(74 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.86 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure LASIK </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There are no data on LASIK for this outcome at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK was ‐0.114 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 higher<br/>(0.11 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment‐procedure LASIK; Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor; proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA); proportion of eyes with optical side effects, such as glare and halo:12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no data on these outcomes at 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded forImprecision.<br/><sup>b</sup>Downgraded for risk of bias.<br/><sup>c</sup>Downgraded for inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012687-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐optimized<br/><b>Comparison:</b> Wavefront‐guided procedure </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Any wavefront‐guided procedure</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Any wavefront‐optimized</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(96 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.99 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>618<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(5 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.96 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 100<br/>(87 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/>(0.95 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK was −0.21 spherical equivalent </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 spherical equivalent higher<br/>(0.03 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure LASIK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure LASIK ranged from 0.26 spherical equivalent </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.14 spherical equivalent lower<br/>(0.19 lower to 0.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 12 months was 0.26 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study that compared wavefront‐optimized LASIK versus wavefront‐guided LASIK reported on loss of 2 or more lines from pretreatment BSCVA that had not returned to baseline by 12 to 24 months after treatment (<a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>). Proportion of eyes with optical side effects, such as glare and halo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias. </p> <p><sup>b</sup>Downgraded for imprecision. </p> <p><sup>c</sup>Downgraded for inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012687-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐guided LASIK<br/><b>Comparison:</b> Wavefront‐guided PRK </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront‐guided PRK</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront‐guided LASIK</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(87 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/>(6 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>882 per 1,000<br/>(745 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.82 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 12 months was −0.17 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(0.18 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HOAs post‐treatment, measured by machine with wavefront sensor ‐ 12 months was 0.38 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/>(0.09 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with optical side effects, such as glare and halo: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for serious imprecision (‐2). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012687-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012687-sec-0009"></div> <section id="CD012687-sec-0010"> <h3 class="title" id="CD012687-sec-0010">Description of the condition</h3> <p>Refractive errors, including myopia, hyperopia and astigmatism of the eye, refer to conditions in which distant objects fail to focus accurately on the retina due to defects in the refractive system. Myopia and hyperopia occur when distant objects focus in front of and behind the retina, respectively. Astigmatism occurs when light rays from distant objects fail to propagate uniformly onto the retina, preventing sharp focus onto the retina and resulting in blurred vision. Myopia, hyperopia and astigmatism are considered lower‐order aberrations, defined as imperfections in image formation due to physical properties of the refractive system (e.g. the shape, curvature, or density of parts of the eye). Aberrations are quantified in terms of Zernike polynomials (e.g. first order, second order, etc.). Eyes with lower‐order aberrations may also have higher‐order aberrations (HOAs), such as spherical aberration, coma, and trefoil, which require special testing and management. </p> <p>Refractive error is the most common cause of visual impairment and the second most frequent cause of treatable blindness worldwide (<a href="./references#CD012687-bbs2-0110" title="ResnikoffS , PascoliniD , MariottiSP , PokharelGP . Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bulletin of the World Health Organization2008;86(1):63-70.">Resnikoff 2008</a>). In the USA and Western Europe, refractive errors affect about one‐third of adults aged 40 years or older (<a href="./references#CD012687-bbs2-0098" title="KempenJH , MitchellP , LeeKE , TielschJM , BromanAT , TaylorHR , et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Archives of Ophthalmology2004;122(4):495-505.">Kempen 2004</a>). In Australia, refractive errors affect one‐fifth of Australians in the same age group. In some East Asian areas, the prevalence of refractive error in adults aged 40 years or older has been estimated to be 32.9% to 57.4% (<a href="./references#CD012687-bbs2-0106" title="LiangYB , WongTY , SunLP , TaoQS , WangJJ , YangXH , et al. Refractive errors in a rural Chinese adult population: the Handan Eye Study. Ophthalmology2009;116(11):2119-27.">Liang 2009</a>). </p> <p>Refractive errors are diagnosed using the spherical equivalent (SE; spherical power +1/2 cylindrical power) of the eyes. Refractive error is diagnosed when the SE is outside the range of −0.50 to +0.50 diopter (D). Myopia and hyperopia are defined as SE less than −0.50 D and greater than +0.50 D, respectively. Astigmatism is measured by off‐axis cylindrical power and the axis that provides the 'circle of least confusion' is recorded. Refractive errors can be measured by using an autorefractor or manually by an optometrist or an ophthalmic technician (for a cooperative participant) using a series of lenses to identify the combination and power that provides the best possible vision (best correction). The best correction for distance viewing typically is recorded, but refraction may also be used to obtain the best correction for near and intermediate viewing, depending upon the participant's needs. HOAs cannot be measured using a traditional autorefractor; they are quantified by wavefront aberration measuring instruments such as an aberrometer with a wavefront sensor where smaller HOAs are better, i.e. represent better optical quality. </p> </section> <section id="CD012687-sec-0011"> <h3 class="title" id="CD012687-sec-0011">Description of the intervention</h3> <p>Spectacles are the simplest, safest, and most common method used to improve distance visual acuity in people with refractive errors. Contact lenses, including soft contact lenses, rigid gas permeable (RGP) lenses and orthokeratology (OK) lenses, are also commonly used for the correction of refractive errors. Soft contact and RGP lenses are worn during waking hours, whereas OK lenses are worn during sleeping hours and have been reported recently to be effective in controlling myopia progression in children (<a href="./references#CD012687-bbs2-0088" title="ChoP , CheungSW . Retardation of Myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Investigative Ophthalmology and Visual Science2012;53(11):7077-85.">Cho 2012</a>; <a href="./references#CD012687-bbs2-0104" title="LiSM , KangMT , WuSS , LiuLR , LiH , ChenZ , et al. Efficacy, safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Current Eye Research2016;41:600-8.">Li 2015</a>). However, when worn, spectacles and contact lenses serve to correct the effects of refractive errors, but do not treat the refractive errors permanently. Additionally, contact lenses may increase the risks of inflammation, conjunctival papillary reaction and even sight‐threatening corneal infection (<a href="./references#CD012687-bbs2-0093" title="FoulksGN . Prolonging contact lens wear and making contact lens wear safer. American Journal of Ophthalmology2006;141(2):369-73.">Foulks 2006</a>). A Cochrane Review in which different interventions for slowing myopia progression in children were compared documented that the most effective treatment option was atropine eyedrops (<a href="./references#CD012687-bbs2-0118" title="WallineJJ , LindsleyKB , VedulaSS , CotterSA , MuttiDO , NgSM , et al. Interventions to slow progression of myopia in children. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD004916. [DOI: 10.1002/14651858.CD004916.pub4]">Walline 2020</a>). <a href="./references#CD012687-bbs2-0103" title="LiSM , WuSS , KangMT , LiuY , JiaSM , LiSY , et al. Atropine slows myopia progression more in Asian than white children by meta-analysis. Optometry and Vision Science2014;91(3):342-50.">Li 2014</a> further found that atropine eyedrops were more effective in Asian children than in white children. However, pharmaceutical interventions do not permanently treat refractive errors, and require repeated instillation during waking hours. They may be associated with undesirable side effects such as burning and stinging during administration, and blurring of vision (<a href="./references#CD012687-bbs2-0118" title="WallineJJ , LindsleyKB , VedulaSS , CotterSA , MuttiDO , NgSM , et al. Interventions to slow progression of myopia in children. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD004916. [DOI: 10.1002/14651858.CD004916.pub4]">Walline 2020</a>). </p> <p>Excimer laser refractive surgery has been a popular and successful method for correcting refractive errors and improving distance visual acuity for about 30 years. Each year, over one million people worldwide undergo excimer laser refractive surgery (<a href="./references#CD012687-bbs2-0112" title="SandovalHP , DonnenfeldED , KohnenT , LindstromRL , PotvinR , TremblayDM , et al. Modern laser in situ keratomileusis outcomes. Journal of Cataract and Refractive Surgery2016;42(8):1224-34.">Sandoval 2016</a>). Excimer laser refractive surgery is designed to correct refractive errors permanently by removing corneal tissues using laser ablation. Excimer laser refractive surgery is performed by creating an epithelial flap ('surface treatment') or corneal flap ('flap treatment') (<a href="./references#CD012687-bbs2-0116" title="ShorttAJ , AllanBD , EvansJR . Laser-assisted in-situ keratomileusis (LASIK) versus photorefractive keratectomy (PRK) for myopia. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD005135. [DOI: 10.1002/14651858.CD005135.pub3]">Shortt 2013</a>). The key difference between surface and flap treatments is the location of the flap, with flap treatments being deeper in the corneal layers than surface treatments. After lifting the flap created with alcohol, blade or laser, another type of laser is used to remove some of the corneal stroma. Surface treatments include photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK) and laser‐assisted in‐situ keratomileusis (LASIK) . Flap treatments include LASIK and sub‐Bowmans keratomileusis (SBK). There is uncertainty as to which method of refractive surgery is most efficacious, accurate, and safe (<a href="./references#CD012687-bbs2-0102" title="KuryanJ , CheemaA , ChuckRS . Laser-assisted subepithelial keratectomy (LASEK) versus laser-assisted in-situ keratomileusis (LASIK) for correcting myopia. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD011080. [DOI: 10.1002/14651858.CD011080.pub2]">Kuryan 2017</a>; <a href="./references#CD012687-bbs2-0105" title="LiSM , ZhanS , LiSY , PengXX , HuJ , LawHA , et al. Laser-assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009799. [DOI: 10.1002/14651858.CD009799.pub2]">Li 2016</a>; <a href="./references#CD012687-bbs2-0115" title="SettasG , SettasC , MinosE , YeungIY . Photorefractive keratectomy (PRK) versus laser assisted in situ keratomileusis (LASIK) for hyperopia correction. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007112. [DOI: 10.1002/14651858.CD007112.pub3]">Settas 2012</a>; <a href="./references#CD012687-bbs2-0116" title="ShorttAJ , AllanBD , EvansJR . Laser-assisted in-situ keratomileusis (LASIK) versus photorefractive keratectomy (PRK) for myopia. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD005135. [DOI: 10.1002/14651858.CD005135.pub3]">Shortt 2013</a>). </p> <p>More recently, the small incision lenticule extraction (SMILE) procedure was invented. It is performed by extracting a refractive lenticule of intrastromal corneal tissue through a small corneal incision without creating a corneal flap (<a href="./references#CD012687-bbs2-0114" title="SekundoW , KunertKS , BlumM . Small incision corneal refractive surgery using the small incision lenticule extraction (SMILE) procedure for the correction of myopia and myopic astigmatism: results of a 6 month prospective study. British Journal of Ophthalmology2011;95(3):335-9.">Sekundo 2011</a>). There are also some procedures, such as intracorneal rings (synthetic devices inserted into the cornea to change its shape) and lenticular refractive procedures (clear lens extraction followed by intraocular lens insertion in the anterior or posterior chamber) that do not require ablation of corneal tissue (<a href="./references#CD012687-bbs2-0087" title="BarsamA , AllanBD . Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD007679. [DOI: 10.1002/14651858.CD007679.pub4]">Barsam 2014</a>). </p> </section> <section id="CD012687-sec-0012"> <h3 class="title" id="CD012687-sec-0012">How the intervention might work</h3> <p>The flap procedures described above are used in both conventional and wavefront refractive surgery. The difference between these two refractive surgeries lies in the procedure of removing corneal stroma. Conventional refractive surgery corrects only for lower‐order aberrations (myopia, hyperopia or astigmatism). In wavefront refractive surgery, three‐dimensional imaging technology is used to identify and correct HOAs. Thus, wavefront refractive surgery theoretically can produce better visual quality than conventional refractive surgery. However, neither type of surgery is without risk of adverse effects. Refractive surgery by excimer laser changes the corneal shape to a more oblate pattern and may introduce HOAs (<a href="./references#CD012687-bbs2-0068" title="PadmanabhanP , MrochenM , BasuthkarS , ViswanathanD , JosephR . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis: contralateral comparative study. Journal of Cataract and Refractive Surgery2008;34(3):389-97. [DOI: 10.1016/j.jcrs.2007.10.028]">Padmanabhan 2008</a>). Nearly 30% of people who have had conventional excimer laser refractive surgery reported symptoms of visual disturbance, such as glare and halos, especially under dim light conditions (<a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>). These procedures may also be associated with new visual symptoms, as seen in 43% of navy personnel (n = 262) and 46% of civilians (n = 312) of similar age (<a href="./references#CD012687-bbs2-0090" title="EydelmanM , HilmantelG , TarverME , HofmeisterEM , MayJ , HammelK , et al. Symptoms and satisfaction of patients in the patient-reported outcomes with laser in Situ Keratomileusis (PROWL) studies. JAMA Ophthalmology2017;135(1):13-22. [PMID: 27893066]">Eydelman 2017</a>). After either conventional or wavefront refractive surgery, antibiotic eyedrops, corticosteroid eyedrops, and artifical tears are generally used for two to four weeks after surgery. </p> <p>Wavefront refractive surgery, including wavefront‐guided or wavefront‐optimized ablations, is based on the analysis of wavefront aberrations (<a href="./references#CD012687-bbs2-0101" title="KruegerRR , RochaKM . Introduction to wavefront-optimized, wavefront-guided, and topography-guided customized ablation: fifth year in review. Journal of Refractive Surgery2008;24(4):S417-8.">Krueger 2008</a>; <a href="./references#CD012687-bbs2-0108" title="MrochenM , KaemmererM , SeilerT . Wavefront-guided laser in situ keratomileusis: early results in three eyes. Journal of Refractive Surgery2000;16(2):116-21.">Mrochen 2000</a>). It corrects spherical and astigmatic refractive errors (lower‐order aberrations), as well as pre‐existing or surgery‐induced HOAs. The wavefront technology analyzes aberrations and applies the information to the laser treatment (<a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>). During the procedure, the treatment area is marked on the visual axis to achieve geometric correspondence of the wavefront aberrations. The ablation of the wavefront aberrations is then performed using a laser with higher frequency and smaller spot diameter than conventional refractive surgery under continuous eye‐tracking control (<a href="./references#CD012687-bbs2-0059" title="MastropasquaL , NubileM , CiancagliniM , TotoL , BalloneE . Prospective randomized comparison of wavefront-guided and conventional photorefractive keratectomy for myopia with the meditec MEL 70 laser. Journal of Refractive Surgery2004;20(5):422-31. ">Mastropasqua 2004</a>). Wavefront‐guided ablations are based on preoperative measurements of HOAs in order to reduce existing HOAs, whereas wavefront‐optimized ablations are designed to minimize induction of new HOAs while preserving naturally‐occurring aberrations of the eye (<a href="./references#CD012687-bbs2-0096" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9.">He 2015</a>). </p> </section> <section id="CD012687-sec-0013"> <h3 class="title" id="CD012687-sec-0013">Why it is important to do this review</h3> <p>Excimer laser refractive surgery is the most common type of surgery used to correct refractive errors (<a href="./references#CD012687-bbs2-0116" title="ShorttAJ , AllanBD , EvansJR . Laser-assisted in-situ keratomileusis (LASIK) versus photorefractive keratectomy (PRK) for myopia. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD005135. [DOI: 10.1002/14651858.CD005135.pub3]">Shortt 2013</a>). With the advancement of technology to facilitate the measurement and treatment of HOAs, custom laser profiles can be used in wavefront‐guided or wavefront‐optimized refractive surgery and have the potential to provide better control of aberrations. A systematic review comparing wavefront versus conventional excimer laser refractive surgery is important to determine whether one procedure results in better visual outcomes for participants. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012687-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012687-sec-0014"></div> <p>The primary objective was to compare the effectiveness and safety of wavefront procedure (wavefront‐optimized or wavefront‐guided (LASIK or PRK or LASEK)) versus corresponding conventional (LASIK or PRK or LASEK) excimer laser refractive surgery, for the correction of refractive errors in adults for postoperative uncorrected visual acuity, residual refractive error, and residual higher‐order aberrations. The secondary objective was to compare wavefront‐optimized versus wavefront‐guided refractive surgery (LASIK or PRK or LASEK). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012687-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012687-sec-0015"></div> <section id="CD012687-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012687-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included only randomized controlled trials (RCTs).</p> </section> <section id="CD012687-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials of participants aged 18 years or older who were randomly assigned to wavefront or conventional excimer laser refractive surgery (PRK or LASIK or LASEK) for any degree of refractive error. We included trials in which a subgroup of participants less than 18 years of age enrolled, when more than 75% of the study population were 18 years or older, or when data for participants 18 years or older were reported separately. We excluded trials that enrolled only participants who had significant coexisting ocular or systematic disease that could have affected refractive status or wound healing, or who had a history of ocular surgery, including refractive surgery. </p> </section> <section id="CD012687-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared the following interventions to manage refractive errors: </p> <p> <ul id="CD012687-list-0001"> <li> <p>wavefront‐guided or ‐optimized refractive surgery versus conventional excimer laser refractive surgery (PRK or LASIK or LASEK); and </p> </li> <li> <p>wavefront‐guided versus wavefront‐optimized refractive surgery (PRK or LASIK).</p> </li> </ul> </p> </section> <section id="CD012687-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012687-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012687-list-0002"> <li> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better at 12 months post‐treatment </p> </li> <li> <p>Proportion of eyes that had lost one or more lines of best spectacle‐corrected visual acuity (BSCVA) at 12 months post‐treatment compared to pre‐surgery measurements </p> </li> </ul> </p> <p>We also analyzed these two outcomes at six months, as a secondary time point.</p> </section> <section id="CD012687-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012687-list-0003"> <li> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction at six and 12 months post‐treatment </p> </li> <li> <p>Mean refractive error expressed as mean spherical equivalent at six and 12 months post‐treatment </p> </li> <li> <p>Mean higher‐order aberrations (HOAs) at 1, 3, 6 and 12 months post‐treatment, measured by machine with wavefront sensor </p> </li> </ul> </p> <p><b>Adverse outcomes</b> </p> <p> <ul id="CD012687-list-0004"> <li> <p>Significant visual loss (loss of two or more lines from pretreatment BSCVA) that did not return within 12 to 24 months of treatment </p> </li> <li> <p>Participant‐reported optical side effects such as glare and halo</p> </li> </ul> </p> </section> </section> </section> <section id="CD012687-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012687-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following databases for randomized controlled trials and controlled clinical trials. There were no restrictions by language or year of publication. The date of the search was 6 August 2019. </p> <p> <ul id="CD012687-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (issue 8, 2019) (<a href="./appendices#CD012687-sec-0100">Appendix 1</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to August 6, 2019) (<a href="./appendices#CD012687-sec-0101">Appendix 2</a>) </p> </li> <li> <p>Embase Ovid (1980 to August 6, 2019 ) (<a href="./appendices#CD012687-sec-0102">Appendix 3</a>) </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information Database (1982 to August 6, 2019) (<a href="./appendices#CD012687-sec-0103">Appendix 4</a>) </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (<a href="./appendices#CD012687-sec-0104">Appendix 5</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) (<a href="./appendices#CD012687-sec-0105">Appendix 6</a>) </p> </li> </ul> </p> </section> <section id="CD012687-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included trials and related systematic reviews to identify further relevant trials. We did not contact manufacturers of laser systems or handsearch journals or conference abstracts for this review. </p> </section> </section> <section id="CD012687-sec-0026"> <h3 class="title" id="CD012687-sec-0026">Data collection and analysis</h3> <section id="CD012687-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SML and SAA) independently screened the titles and abstracts of all records identified by the searches and assessed the relevance of each record using <a href="./references#CD012687-bbs2-0089" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed 6 July 2019. Available at covidence.org.">Covidence</a> software. We resolved discrepancies by discussion or by a third review author (NLW). We obtained full‐text copies of reports of potentially relevant studies. Two review authors (SML and SAA) independently assessed the full‐text reports according to the definitions in <a href="#CD012687-sec-0016">Criteria for considering studies for this review</a> and classified each study as 'include', 'exclude', or 'uncertain'. Whenever we deemed eligibility as uncertain because insufficient information was provided in the study reports, we contacted study authors for more information. The review authors were unmasked to the trial authors, institution and trial results during the assessment. We resolved any discrepancies by discussion or by consultation with a third review author (NLW). Excluded studies, along with the reasons for exclusion, are documented in the '<a href="./references#CD012687-sec-0117" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD012687-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SML and MTK) independently extracted data from each eligible study onto a web‐based, electronic data collection form in <a href="./references#CD012687-bbs2-0089" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed 6 July 2019. Available at covidence.org.">Covidence</a>. Data items extracted included the following: </p> <p> <ul id="CD012687-list-0006"> <li> <p>Study characteristics: country, setting, status of publication, publication year, title, authors, source, contact address, and funding sources; </p> </li> <li> <p>Methods: study duration, randomization technique, method of allocation concealment before randomization, masking (participants, provider, outcome assessors), analysis methods for outcomes; </p> </li> <li> <p>Participants: eligibility criteria, number in each intervention group, age, gender, similarity of intervention groups at baseline, withdrawals/losses to follow‐up (reason) and subgroups for whom outcomes were reported; </p> </li> <li> <p>Interventions: types of refractive surgery (details of procedure), and medical or other adjunctive treatment (dose, route, duration); </p> </li> <li> <p>Outcomes: outcomes specified above, any other outcomes reported, other events, times of assessment and length of follow‐up of individual participants. Definitions and methods for ascertaining outcomes have been checked for consistency among studies. </p> </li> </ul> </p> <p>Whenever there were data items that we needed to clarify or expand, we contacted the authors of trial reports or organizations that sponsored the trial. We made three attempts (at two‐week intervals) to contact trial investigators by email. When we received no response after three attempts, we used data available in the trial reports. When data were shown only in figures (for example, mean and standard deviations) and could not be obtained from the authors, we used GetData Graph Digitizer 2.24 (<a href="http://getdata-graph-digitizer.com" target="_blank">getdata-graph-digitizer.com</a>) to estimate data values from the figures. We resolved discrepancies by discussion, referring back to the original article or by consultation with a third review author (NLW). One review author entered data into Review Manager 5 (RevMan 5) (<a href="./references#CD012687-bbs2-0111" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2019.">Review Manager 2019</a>); a second review author verified the accuracy of data entry. </p> </section> <section id="CD012687-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SML and SAA) independently assessed each included trial for risks of bias according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012687-bbs2-0097" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , Sterne JA (editors). Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We judged risks of bias using domain‐based evaluations of selection bias (random sequence generation, allocation concealment before randomization), performance bias (masking of participants and study personnel), detection bias (masking of outcome assessors), attrition bias (amount and handling of missing data) and reporting bias (selective outcome reporting). We judged each trial for each 'Risk of bias' domain to be at 'low risk', 'high risk' or 'unclear risk' for the specific bias. We resolved all discrepancies between judgments of review authors by discussion or by seeking an opinion from a third review author (MTK). We contacted trial authors to clarify any bias domain graded as 'unclear risk' due to lack of information. </p> </section> <section id="CD012687-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated risk ratios (RRs) with corresponding 95% confidence intervals (CIs). Dichotomous outcomes planned for this review include the proportion of eyes with UCVA of 20/20 or better, proportion of eyes that lost one or more lines of BSCVA, proportion of eyes within ± 0.50 D of target refraction, proportion of eyes with an adverse outcome (significant permanent visual loss or optical side effect). For continuous outcomes, we calculated mean differences (MDs) with corresponding 95% CIs. Continuous outcomes planned for this review include mean postoperative spherical equivalent and high‐order aberrations (HOAs). </p> </section> <section id="CD012687-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The ideal unit of analysis is the individual (one study eye per participant). However, we acknowledge that some trials may have used a paired‐eye design, where one eye was randomized to one intervention and the contralateral eye was randomized to the other intervention. We included these trials, as well as trials in which both eyes of a participant were randomized to the same intervention. We documented when both eyes of a participant were included in a trial and assessed whether the data analysis appropriately accounted for the non‐independence of eyes. For trials with multiple treatment groups, we included only the treatment groups relevant to this review (i.e. groups treated with wavefront or conventional excimer laser refractive surgery). </p> </section> <section id="CD012687-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing from trial reports or were unclearly reported, we first contacted the trial authors to obtain supplemental information. When we were unable to obtain or confirm numerical data that were displayed only in figures from trial authors, we extracted the data using the software Get Data Graph Digitizer 2.24 (<a href="http://getdata-graph-digitizer.com" target="_blank">getdata-graph-digitizer.com</a>). We did not impute data for the purposes of this review; however, we used trial results when available, when the trial investigators had performed and reported appropriate imputation. We had planned to perform sensitivity analysis to examine the potential impact of trials assessed at high risk of attrition bias, by excluding these trials from our analysis. We did not do this because most included studies were either at high or unclear risk of attrition bias. </p> </section> <section id="CD012687-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity among trials to determine whether meta‐analysis was appropriate. When we found substantial clinical or methodological heterogeneity, we did not combine studies quantitatively, but rather presented a narrative summary of the trial results. When trials were clinically and methodologically similar (homogeneous), we combined data using meta‐analysis. We assessed statistical heterogeneity using a Chi<sup>2</sup> test (with a 10% or smaller probability level suggesting heterogeneity), the I<sup>2</sup> statistic (60% and more representing substantial statistical heterogeneity), and visual inspection of forest plots for consistency in the direction of estimates and overlap of CIs among studies. </p> </section> <section id="CD012687-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We had planned to assess potential publication bias using funnel plots when 10 or more trials were included in a meta‐analysis. An asymmetrical funnel plot may be the result of factors such as publication bias, heterogeneity of effects or differences in the methodological quality of studies. However, there were fewer than 10 studies for any given outcome in our meta‐analysis, so it was not possible to assess publication bias. We also evaluated selective outcome reporting as part of our assessment of risk of bias in included studies. </p> </section> <section id="CD012687-sec-0035"> <h4 class="title">Data synthesis</h4> <p>When we found substantial statistical heterogeneity, we rechecked the data entered into RevMan 5 software. When the data had been confirmed to be correct and the direction of effects remained inconsistent, we considered whether combination of the data across studies was appropriate. We conducted subgroup analyses to explore heterogeneity according to predetermined characteristics defined in the section Subgroup analysis and investigation of heterogeneity. We used random‐effects model for all analysis. </p> </section> <section id="CD012687-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to perform subgroup analysis according to the following ranges of myopia: low to moderate myopia (&lt; −0.50 to −6.00 D) and moderate to high myopia (&lt; −6.00 to −15.00 D). We did not conduct these analyses because of insufficient data. We also performed subgroup analysis for laser platform, ablation algorithm and method for creating corneal flap (PRK or LASIK) when comparing wavefront‐guided or wavefront‐optimized refractive surgery (wavefront) versus conventional excimer laser refractive surgery and when comparing wavefront‐guided versus wavefront‐optimized refractive surgery. We considered other factors such as age and race for subgroup analysis when there was sufficient information reported in the included trials. We documented and provided a rationale for any post hoc subgroup analysis. </p> </section> <section id="CD012687-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to examine the impact of restricting the analysis to studies of high methodological quality as reflected in low overall risk of bias assessment across 'Risk of bias' domains assessed, as well as the impact of excluding unpublished data, on the effect estimates. However, we did not perform these analyses because we rated none of the included studies at overall low risk of bias and we obtained no unpublished data. We evaluated the effect of excluding from the analyses studies that provided extreme estimates of intervention effects compared to other studies (outliers) or studies conducted among participants with hyperopia as part of a sensitivity analysis to explore their impact on the effect estimates. We also assessed the impact of excluding industry‐funded studies on the effect estimates in a sensitivity analysis. Post hoc, we had planned to assess the impact of restricting our analysis to studies that analyzed data at the participant rather than at the eye level. We did not perform this analysis because of an insufficient number of studies with these characteristics. </p> </section> <section id="CD012687-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We summarized the main findings for each comparison of interest, including strengths and limitations of evidence for primary, secondary, and adverse outcomes, using the GRADE approach (<a href="./references#CD012687-bbs2-0095" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 10 Janauary 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We assessed the certainty of evidence for each outcome as 'high,' 'moderate,' 'low,' or 'very low' according to the following criteria as described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012687-bbs2-0113" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). </p> <p> <ul id="CD012687-list-0007"> <li> <p>High risk of bias among included studies.</p> </li> <li> <p>Indirectness of evidence.</p> </li> <li> <p>Unexplained heterogeneity or inconsistency of results.</p> </li> <li> <p>Imprecision of results (i.e. wide confidence intervals).</p> </li> <li> <p>High probability of publication bias.</p> </li> </ul> </p> <p>We downgraded the certainty of evidence by one point for each of the above deficiencies. We present a 'Summary of findings' table (<a href="./full#CD012687-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012687-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012687-tbl-0003">summary of findings Table 3</a>) for each comparison of interest when data were available. The comparisons include: </p> <p> <ul id="CD012687-list-0008"> <li> <p>wavefront‐optimized or ‐guided refractive surgery (wavefront) versus conventional excimer laser refractive surgery; </p> </li> <li> <p>wavefront‐optimized versus wavefront‐guided refractive surgery; and</p> </li> <li> <p>wavefront‐guided PRK versus wavefront‐guided LASIK.</p> </li> </ul> </p> <p>We included the following seven outcomes at 12 months post‐treatment in the 'Summary of findings' tables. </p> <p> <ul id="CD012687-list-0009"> <li> <p>Proportion of eyes with UCVA of 20/20 or better;</p> </li> <li> <p>Proportion of eyes that had lost one or more lines of BSCVA;</p> </li> <li> <p>Proportion of eyes within ± 0.50 D of target refraction;</p> </li> <li> <p>Mean refractive error expressed as mean spherical equivalent;</p> </li> <li> <p>Mean HOAs, measured by machine with wavefront sensor;</p> </li> <li> <p>Proportion of eyes with significant visual loss (loss of two or more lines from pretreatment BSCVA); </p> </li> <li> <p>Proportion of eyes with optical side effects, such as glare and halo.</p> </li> </ul> </p> <p>Because of a paucity of data for outcomes at 12 months, we decided post hoc to include more 'Summary of finding' tables as Additional tables for outcomes at six months. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012687-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012687-sec-0039"></div> <section id="CD012687-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD012687-sec-0041"> <h4 class="title">Results of the search</h4> <p>Electronic databases searched on 6 August 2019 yielded 1161 records; we added five records after searching the reference lists of included studies (<a href="#CD012687-fig-0001">Figure 1</a>). We excluded 1061 records for studies that did not meet the eligibility criteria based on a review of titles and abstracts. We retrieved 100 full‐text records and further assessed them for eligibility, of which we excluded 50 and recorded reasons for exclusion (<a href="./references#CD012687-sec-0117" title="">Characteristics of excluded studies</a>). We classified the records of two studies as awaiting classification and included 48 records of 33 studies in the review. There were 5, 5 and 8 records from <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>, <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a> and <a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>, respectively. There were no ongoing or unpublished studies identified from registers. </p> <div class="figure" id="CD012687-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012687-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD012687-sec-0043"> <h5 class="title">Types of studies</h5> <p>The 33 studies enrolled a total of 1499 adult participants (2797 eyes) with refractive errors that ranged from high myopia to low hyperopia. Studies were published from 2002 to 2019 and seven of the 33 were registered; participant follow‐up ranged from one month to 12 months. Two studies assessed interventions for hyperopia (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>) and the other 31 compared interventions for myopia. The studies were conducted mostly in the USA (15), but also in China (5), Iran (3), Korea (3), UK (2) Thailand (2) and one study each from Italy, Ireland and The Netherlands. In three of the 33 studies, one eye of each participant was randomized to each intervention group (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>), in eight studies both eyes of participants were in the same intervention group (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>; <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>), two studies did not report on how eyes were assigned to intervention (<a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>), and the remaining 20 studies used paired‐eyes designs, where correlated eyes of the same participant were in different intervention groups. </p> </section> <section id="CD012687-sec-0044"> <h5 class="title">Types of participant</h5> <p>The sample size of included trials ranged from nine (<a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>) to 108 (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>) participants per trial. Some of the studies did not report the age or gender of participants. Among 24 trials with information on age and gender, participants were predominantly women, with mean ages ranging between 29 and 53 years. Preoperative spherical equivalent refraction of participants ranged from −3.26 to −4.45 diopters (D) in the wavefront‐optimized PRK group and −3.34 to −4.66 D in the wavefront‐guided PRK group. In the wavefront‐optimized LASIK group, preoperative spherical equivalent refraction ranged from +1.93 to −4.61 D; +1.73 to −4.56 D in the wavefront‐guided LASIK group; −2.25 to −4.57 D in the wavefront‐guided PRK group, and −2.35 to −4.58 D in the conventional PRK group; −1.81 to −7.18 D in the conventional LASIK group and −2.01 to −7.09 D in the wavefront‐guided LASIK group; −2.99 D in the conventional PRK group and −2.60 in the wavefront‐optimized PRK group; +1.75 D in the conventional LASIK (hyperopia) and +1.52 D in the wavefront‐optimized LASIK (hyperopia) group; −7.25 ± 3.47 (−5.50 to −10.75) D in both conventional LASEK group and wavefront‐guided LASEK groups; −4.39 in the wavefront‐guided PRK and −4.46 in the wavefront‐guided LASIK. </p> </section> <section id="CD012687-sec-0045"> <h5 class="title">Types of intervention</h5> <p>We categorized the comparisons into two main groups, as wavefront procedure (wavefront‐optimized or wavefront‐guided (LASIK or PRK or LASEK)) versus corresponding conventional procedure (LASIK or PRK or LASEK), and wavefront‐optimized (LASIK or PRK) versus wavefront‐guided (LASIK or PRK), and added a third comparison of wavefront‐guided LASIK versus wavefront‐guided PRK. </p> <p>Twenty studies compared a wavefront procedure versus the corresponding conventional procedure. Of these, 15 assessed a wavefront LASIK procedure versus conventional LASIK procedure (<a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0019" title="MercheaMM , MatthaeusA , CoxIG . Visual performance improvement in Zyoptix wavefront guided LASIK. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 204. ">Merchea 2004</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>; <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>); one study compared wavefront‐guided LASEK with conventional LASEK (<a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>), and four studies assessed a wavefront PRK procedure versus conventional PRK (<a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>). Among the 13 studies that assessed wavefront‐optimized (LASIK or PRK) versus wavefront‐guided (LASIK or PRK), eight studies assessed wavefront‐optimized LASIK versus wavefront‐guided LASIK procedure (<a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>; <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>), four compared wavefront‐optimized PRK versus wavefront‐guided PRK procedure (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0022" title="MoshirfarM , ChurginDS , BettsBS , HsuM , SikderS , NeufferM , et al. Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations. Clinical Ophthalmology2011;5:1185-93. [DOI: https://dx.doi.org/10.2147/OPTH.S24319]">Moshirfar 2011a</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>) and one study assessed wavefront‐guided LASIK versus wavefront‐guided PRK (<a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>). </p> </section> <section id="CD012687-sec-0046"> <h5 class="title">Types of outcome</h5> <section id="CD012687-sec-0047"> <h6 class="title">Visual acuity outcomes</h6> <p>Seven studies reported data on the proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better at 12 months post‐treatment (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>;) and 11 studies reported this outcome at six months (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). Five studies reported data on the proportion of eyes that had lost one or more lines of best spectacle‐corrected visual acuity (BSCVA) at 12 months post‐treatment (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) and six studies reported the outcome at six months (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>). Six studies each reported data on loss of one or more lines of BSCVA at 12 months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) and at six months (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>). </p> </section> <section id="CD012687-sec-0048"> <h6 class="title">Refraction outcomes</h6> <p>Seven studies reported on the proportion of eyes with refractive error within ± 0.50 D of target at 12 months post‐treatment (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) and at six months post‐treatment in nine studies (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). Seven studies reported mean refractive error expressed as mean spherical equivalent post‐treatment at 12 months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) and 15 studies at six months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>). </p> </section> <section id="CD012687-sec-0049"> <h6 class="title">Higher‐order aberration outcomes</h6> <p>Mean higher‐order aberrations (HOAs) post‐treatment were reported in 10 studies at one month (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a>); 19 studies at three months (<a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0022" title="MoshirfarM , ChurginDS , BettsBS , HsuM , SikderS , NeufferM , et al. Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations. Clinical Ophthalmology2011;5:1185-93. [DOI: https://dx.doi.org/10.2147/OPTH.S24319]">Moshirfar 2011a</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>); 12 studies at six months (<a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>) and seven studies at 12 months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>). </p> </section> <section id="CD012687-sec-0050"> <h6 class="title">Adverse outcomes</h6> <p>One study reported on the loss of two or more lines from pretreatment BSCVA that had not returned to baseline by 12 to 24 months after treatment (<a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>). Nine studies provided information on other optical side effects (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>). </p> </section> <section id="CD012687-sec-0051"> <h6 class="title">Funding sources and declarations of interest</h6> <p>Investigators from 12 studies reported their source of funding for their studies or reported receiving no funding. Two studies were US‐government funded (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>), three studies were industry‐funded (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>), seven reported no funding (<a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0022" title="MoshirfarM , ChurginDS , BettsBS , HsuM , SikderS , NeufferM , et al. Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations. Clinical Ophthalmology2011;5:1185-93. [DOI: https://dx.doi.org/10.2147/OPTH.S24319]">Moshirfar 2011a</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>), and reports from 21 studies had no information on funding source. Eight of the 33 studies did not report any conflict of interest (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). Of the 25 studies for which investigators declared conflicts of interest, at least one author in 10 studies reported either having equity or consulting for industries that were also a manufacturer of at least one of the intervention devices evaluated (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0019" title="MercheaMM , MatthaeusA , CoxIG . Visual performance improvement in Zyoptix wavefront guided LASIK. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 204. ">Merchea 2004</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>). Authors of the remaining 15 trials reported having no conflict of interest. </p> </section> </section> </section> <section id="CD012687-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 50 records after review of full‐text reports: 27 reports were not RCTs, 20 reports used interventions or comparison interventions that were not specific to the review and three focused on populations not of interest. Detailed reasons for exclusion of each trial are given in the table of <a href="./references#CD012687-sec-0117" title="">Characteristics of excluded studies</a>. We did not identify any ongoing studies. </p> </section> </section> <section id="CD012687-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>We show our judgements of the risks of bias in each domain for each study in <a href="#CD012687-fig-0002">Figure 2</a>, and summarize the risk of bias for each domain among all included trials in <a href="#CD012687-fig-0003">Figure 3</a>. In summary, we judged no study among the 33 included to be at overall low risk of bias. All trials were reported in insufficient detail to judge the potential for most sources of bias assessed. Of note, risk of bias for 10 trials: <a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a> and <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a> could not be judged for any domains assessed, due to insufficient information provided by these trials. </p> <div class="figure" id="CD012687-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012687-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012687-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012687-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012687-sec-0054"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>Eighteen of the 33 included trials (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0022" title="MoshirfarM , ChurginDS , BettsBS , HsuM , SikderS , NeufferM , et al. Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations. Clinical Ophthalmology2011;5:1185-93. [DOI: https://dx.doi.org/10.2147/OPTH.S24319]">Moshirfar 2011a</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>) used an adequate method to generate the random sequence of assignments to intervention and we judged them as low risk of bias. The remaining 15 trials did not describe the method of randomization used, and were classified as having unclear risk of bias. </p> <p><b>Allocation concealment</b> </p> <p>Four studies (<a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>) used adequate methods to conceal the treatment allocation before the random assignment was revealed and were judged at low risk of bias. The remaining 29 studies were judged at unclear risk of bias because they did not report whether or how treatment allocation was concealed. </p> </section> <section id="CD012687-sec-0055"> <h4 class="title">Blinding</h4> <p><b>Performance bias</b> <br/>Five studies (<a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>) were judged to be at low risk of bias as participants and personnel were adequately masked to the treatment for each eye. Two studies (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>) were open‐label and were judged to be at high risk for performance bias. The remaining 26 studies were judged to have unclear risk of bias due to unclear reporting.<br/><br/><b>Detection bias</b><br/><br/>One study was judged to be at low risk of detection bias, as the outcome assessor was adequately masked (<a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>). The remaining 32 studies were judged to be at unclear risk of detection bias due to unclear reporting. </p> </section> <section id="CD012687-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>Eleven studies (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>) were judged to be at low risk of attrition bias as there were no losses to follow‐up and therefore incomplete outcome data were minimal. Three studies (<a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0019" title="MercheaMM , MatthaeusA , CoxIG . Visual performance improvement in Zyoptix wavefront guided LASIK. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 204. ">Merchea 2004</a>) were judged to be at high risk of attrition bias as there were high losses to follow‐up. We judged the remaining 19 studies to be at unclear risk of bias due to insufficient information about incomplete outcome data because of poor reporting. </p> </section> <section id="CD012687-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We judged six studies at low risk of bias for selective outcome reporting based on comparison with a published protocol, trial registration record, or comparison of the outcomes reported with those stated in study methods (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>). We judged two trials (<a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) to be at high risk of bias for selective outcome reporting, since not all outcomes specified in registration records for those trials were reported. The remaining 25 studies were judged to be at unclear risk of bias for selective reporting because outcomes reported were either not stated in the study methods or we were unable to find a protocol or trial register record to ascertain consistency between prespecified outcomes and those reported from the study. </p> </section> </section> <section id="CD012687-sec-0058"> <h3 class="title" id="CD012687-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD012687-tbl-0001"><b>Summary of findings 1</b> Wavefront procedures compared to conventional procedures for adults with refractive errors</a>; <a href="./full#CD012687-tbl-0002"><b>Summary of findings 2</b> Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</a>; <a href="./full#CD012687-tbl-0003"><b>Summary of findings 3</b> Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</a> </p> <p>Outcomes from six of the 33 trials (<a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0019" title="MercheaMM , MatthaeusA , CoxIG . Visual performance improvement in Zyoptix wavefront guided LASIK. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 204. ">Merchea 2004</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>; <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a>) were not included in quantitative synthesis because they either did not report primary or secondary outcome data of interest or reported data in a format insufficient for analysis. We therefore include 27 trials in meta‐analyses. </p> <section id="CD012687-sec-0059"> <h4 class="title">Comparison 1. Wavefront versus corresponding conventional procedures</h4> <p>Nineteen studies compared either a wavefront‐optimized or wavefront‐guided LASIK or PRK with the corresponding conventional procedure: (<a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0006" title="D'ArcyF , KirwanC , QasemQ , O'KeefeM . Prospective contralateral eye study to compare conventional and wavefront-guided laser in situ keratomileusis. Acta Ophthalmologica2012;90(1):76-80. [DOI: 10.1111/j.1755-3768.2009.01845.x]">D'Arcy 2012</a>; <a href="./references#CD012687-bbs2-0007" title="DurrieDS , StahlJ . Randomized comparison of custom laser in situ keratomileusis with the Alcon CustomCornea and the Bausch &amp; Lomb Zyoptix systems: one-month results. Journal of Refractive Surgery2004;20(5):S614-8. [PMID: 15523985]">Durrie 2004</a>; <a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0019" title="MercheaMM , MatthaeusA , CoxIG . Visual performance improvement in Zyoptix wavefront guided LASIK. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 204. ">Merchea 2004</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0029" title="SmithGT , SmithLF , StevensJD . Randomised prospective double masked study of wavefront-guided LASIK treatment to one eye and non-wavefront guided treatment to the contralateral eye. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2822. ">Smith 2004</a>; <a href="./references#CD012687-bbs2-0030" title="VongthongsriA , PhusitphoykaiN , NaripthapanP . Comparison of wavefront-guided customized ablation vs. conventional ablation in laser in situ keratomileusis. Journal of Refractive Surgery2002;18(Suppl 3):S332-5. ">Vongthongsri 2002</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>; <a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a>). However not all studies reported all outcomes of interest. One study compared wavefront‐guided LASEK with conventional LASEK (<a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>). </p> <section id="CD012687-sec-0060"> <h5 class="title">Proportion of eyes with UCVA of 20/20 or better</h5> <p>Proportion of eyes with UCVA of 20/20 or better when examined six months after refractive surgery was reported in six studies (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0025" title="NuijtsRM , NabarVA , HamentWJ , EgginkFA . Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. Journal of Cataract and Refractive Surgery2002;28(11):1907-13. ">Nuijts 2002</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>), but only <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a> reported this outcome at 12 months. The estimated RR at six months, along with its 95% confidence interval (CI) was: overall: RR 1.00, 95% CI 0.96 to 1.03; I<sup>2</sup> = 0%; 6 studies, 470 participants. When examined by subgroup, effect estimates from the two studies of PRK are: RR 0.95, 95% CI 0.81 to 1.12; I<sup>2</sup> = 0%; 2 studies, 136 participants, and from the four studies of LASIK: RR 1.00, 95% CI 0.96 to 1.04; I<sup>2</sup> = 0%; 4 studies, 334 participants. Thus, we combined data from all 470 participants in all six studies among subgroups of participants in studies of PRK or LASIK and found no statistically or clinically significant difference between wavefront and conventional refractive surgery for achieving UCVA of 20/20 or better six months after surgery (<a href="#CD012687-fig-0004">Figure 4</a>; <a href="./references#CD012687-fig-0007" title="">Analysis 1.1</a>). We rated the certainty of evidence for the overall outcome at six months and for subgroup outcomes as low, owing to risk of bias and imprecision. <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a> was the only study in which UCVA of 20/20 or better was reported at 12 months after surgery. The estimated RR of wavefront‐guided PRK compared with conventional PRK was 1.03 (95% CI 0.86 to 1.24; 70 participants; <a href="./references#CD012687-fig-0008" title="">Analysis 1.2</a>). The 12‐month effect estimate is consistent with the six‐month estimates, indicating no benefit of wavefront‐guided PRK relative to conventional PRK for this outcome. The certainty of evidence was low, downgraded for risk of bias and imprecision. </p> <div class="figure" id="CD012687-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months." data-id="CD012687-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months. </p> </div> </div> </div> </section> <section id="CD012687-sec-0061"> <h5 class="title">Proportion of eyes without loss of BSCVA</h5> <p>Proportion of eyes without loss of one or more lines of BSCVA from presurgical levels when examined six or 12 months after surgery was reported by three studies at six months (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>), but only by <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a> at 12 months. The six‐month and 12‐month effect estimates from <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>, in which wavefront‐guided PRK was compared with conventional PRK were: RR 1.00, 95% CI 0.93 to 1.07; 80 participants at six months (<a href="./references#CD012687-fig-0009" title="">Analysis 1.3</a>), and: RR 0.94, 95% CI: 0.81 to 1.09; 70 participants at 12 months (<a href="./references#CD012687-fig-0010" title="">Analysis 1.4</a>). For this outcome among the 71 participants in the two studies in which LASIK procedures were compared, the estimated effect at six months was: RR 1.11, 95% CI 0.88 to 1.40; I<sup>2</sup> = 59%. The overall effect estimate was: RR 1.04, 95% CI 0.93 to 1.17; I<sup>2</sup> = 45%; 3 studies, 151 participants at six months. Neither at six nor at 12 months after surgery nor by type of refractive corneal procedure (PRK or LASIK) was there a clinically or statistically important difference between the wavefront and conventional interventions for this outcome. We graded the certainty of evidence for the overall outcome and outcomes by subgroups at six and 12 months as low, due to risk of bias and imprecision. </p> </section> <section id="CD012687-sec-0062"> <h5 class="title">Proportion of eyes within ± 0.5 diopters of target refraction</h5> <p>Effect estimates of the proportions of eyes in which the refractive error was within ±0.5 D of the target refraction were based on findings reported for 212 participants in four studies at six months (<a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>) and for 70 participants in one of the four studies at 12 months (<a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>). Due to inconsistency in the direction of effect estimates from individual studies, we considered it inappropriate to combine the data across studies of PRK and LASIK into an overall effect estimate at six months. Effect estimates for subgroups were: for the three studies of PRK: RR 0.89, 95% CI 0.78 to 1.01; I<sup>2</sup> = 32%; 192 participants; and one study of LASIK: RR 1.11, 95% CI 0.85 to 1.44; 20 participants (<a href="#CD012687-fig-0005">Figure 5</a>; <a href="./references#CD012687-fig-0011" title="">Analysis 1.5</a>). None of the effect estimates for the subgroups showed any evidence of a difference between the wavefront and the conventional procedure groups. The effect estimate at 12 months from one study also showed no evidence of a difference between the groups: RR 1.03, 95% CI 0.86 to 1.24; 70 participants; <a href="./references#CD012687-fig-0012" title="">Analysis 1.6</a>. The certainty of evidence for this outcome at both time points was very low, downgrading for risk of bias, imprecision and inconsistency. </p> <div class="figure" id="CD012687-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months." data-id="CD012687-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months. </p> </div> </div> </div> </section> <section id="CD012687-sec-0063"> <h5 class="title">Mean refractive error, spherical equivalent</h5> <p>Data for this outcome at six months were available for eight trials (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a>; <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>; <a href="./references#CD012687-bbs2-0026" title="PhusitphoykaiN , TungsiripatT , SiriboonkoomJ , VongthongsriA . Comparison of conventional versus wavefront-guided laser in situ keratomileusis in the same patient. Journal of Refractive Surgery2003;19(Suppl 2):S217-20. ">Phusitphoykai 2003</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>; <a href="./references#CD012687-bbs2-0031" title="YuJ , WangF . Contrast sensitivity change after wavefront-guided laser in situ keratomileusis. Chinese ophthalmic research2007;25(2):138-141. ">Yu 2007</a>), but at 12 months only for <a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>. At six months, no overall mean difference (MD) in refractive error was calculated, due to substantial heterogeneity. The effect estimate for studies of PRK was: MD 0.06 D, 95% CI −0.09 D to 0.21 D; 3 studies, 196 participants, and that for studies of LASIK was: MD 0.11 D, 95% CI −0.05 D to 0.28 D; I<sup>2</sup>=83%; 5 studies, 428 participants (<a href="#CD012687-fig-0006">Figure 6</a>; <a href="./references#CD012687-fig-0013" title="">Analysis 1.7</a>). The effect estimates for the subgroups based on the type of refractive corneal procedure (PRK or LASIK) showed no evidence of a difference between the wavefront and the conventional procedures. Statistical heterogeneity for the estimates of the LASIK subgroup was high (I<sup>2</sup>=83%) . At 12 months, the estimated mean refractive error based on data for 70 participants in a single trial also showed no evidence of effect: MD 0.04 D, 95% CI −0.11 to 0.18. At neither six months, 12 months nor by type of refractive corneal procedure (PRK or LASIK) do the effect estimates suggest a consistent statistically or clinically important difference between wavefront procedures and conventional procedures. The certainty of evidence for this outcome at both time points as well as by type of procedure was very low, after downgrading for risk of bias, inconsistency and imprecision. </p> <div class="figure" id="CD012687-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months." data-id="CD012687-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. </p> </div> </div> </div> </section> <section id="CD012687-sec-0064"> <h5 class="title">Higher‐order aberrations (HOAs) post‐treatment</h5> <p>No study reported mean HOAs at 12 months post‐treatment for this outcome. However, mean HOAs at one month post‐surgery were reported by three studies (<a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>), at three months by five studies (<a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>; <a href="./references#CD012687-bbs2-0005" title="ChenGM , WangSY , LiuS , MaN , SunXJ , PanJ . Clinical experience on LASEK operation treated with wavefront guided techniques. International Journal of Ophthalmology2010;10(11):2124-5. [DOI: 10.3969/j.issn.1672-5123.2010.11.026]">Chen 2010</a>; <a href="./references#CD012687-bbs2-0010" title="KimTI , YangSJ , TchahH . Bilateral comparison of wavefront-guided versus conventional laser in situ keratomileusis with Bausch and Lomb Zyoptix. Journal of Refractive Surgery2004;20(5):432-8. ">Kim 2004</a>; <a href="./references#CD012687-bbs2-0011" title="LeeDH , JaeRO , ReinsteinDZ . Conservation of corneal tissue with wavefront-guided laser in situ keratomileusis. Journal of Cataract and Refractive Surgery2005;31(6):1153-8. [DOI: http://dx.doi.org/10.1016/j.jcrs.2004.12.039]">Lee 2005</a>; <a href="./references#CD012687-bbs2-0024" title="NassiriN , SafiS , AghazadeAM , SheibaniK , SafiH , PanahiN , et al. Visual outcome and contrast sensitivity after photorefractive keratectomy in low to moderate myopia: wavefront-optimized versus conventional methods. Journal of Cataract and Refractive Surgery2011;37(10):1858-64. [DOI: 10.1016/j.jcrs.2011.05.023]">Nassiri 2011</a>), and at six months by five studies (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). We graded the certainty of evidence for HOAs at both one and three months as moderate, downgrading for risk of bias, and rated the certainty of evidence for this outcome at six months as very low, downgrading for risk of bias, inconsistency and imprecision. </p> <p>Estimated mean HOAs from meta‐analysis of findings from these studies by post‐surgery times are provided below. </p> <section id="CD012687-sec-0065"> <h6 class="title">One month:</h6> <p>No overall effect estimate was calculated, because of substantial heterogeneity. No study of PRK reported mean HOAs at one month. Data from two studies of LASIK with 68 participants suggest a benefit in favor of the wavefront procedure at one month (MD −0.12, 95% CI −0.22 to −0.03; I<sup>2</sup> = 0%). The evidence favored wavefront‐guided LASIK compared to conventional LASIK. The effect estimate for LASEK among 80 participants was: MD −0.31, 95% CI −0.38 to −0.23; I<sup>2</sup> = 0%; 1 study ( <a href="./references#CD012687-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD012687-sec-0066"> <h6 class="title">Three months:</h6> <p>No overall estimates were calculated due to substantial heterogeneity among subgroups being evaluated (I<sup>2</sup> = 96%). The effect estimates at three months were as follows: studies of PRK: MD −0.04, 95% CI −0.10 to 0.02; 1 study, 132 participants; studies of LASIK: MD −0.02, 95% CI −0.04 to 0.00; I<sup>2</sup> = 0%; 3 studies, 92 participants; and one study of LASEK: MD −0.23, 95% CI −0.26 to −0.19; 1 study, 80 participants (<a href="./references#CD012687-fig-0016" title="">Analysis 1.10</a>). One study of LASIK that was reported only in an abstract estimated the difference to be MD −0.02, 95% CI −0.04 to 0.00; 1 study, 24 participants; however, the standard deviations (SDs) reported were very small for a study with so few participants, leading us to suspect that standard errors (SEs) had been calculated rather than SDs. If our suspicion is correct, it would explain the extreme weight given to the estimates from <a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>. When we removed <a href="./references#CD012687-bbs2-0001" title="AndersonDF , ChisholmCM , KhanA , KvansakulJ , BarburJL , GartryDS . Prospective, randomised, double-masked pilot study of conventional versus wavefront-guided LASIK: visual and refractive outcomes. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 1101. ">Anderson 2004</a>, the effect estimate was: MD −0.04, 95% CI −0.15 to 0.06; I<sup>2</sup> = 0%; 2 studies, 68 participants. </p> </section> <section id="CD012687-sec-0067"> <h6 class="title">Six months:</h6> <p>Data were available for two studies of PRK. Due to substantial heterogeneity, we did not combine data in a meta‐analysis. While point estimates from <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a> (MD −0.21, 95% CI −0.26 to −0.16) suggest a benefit for wavefront‐guided PRK relative to conventional PRK based on 56 eyes of 56 participants, the estimate from <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a> (MD 0.17, 95% CI 0.02 to 0.32) favors conventional PRK (56 eyes, 28 participants). </p> </section> <section id="CD012687-sec-0068"> <h6 class="title">12 months:</h6> <p>No 12‐month data were available for this outcome. Heterogeneity was high in subsets of studies for this outcome, except for three‐month estimates from trials of LASIK and LASEK. The three‐month estimates of LASIK and LASEK tended to favor wavefront over conventional procedures. </p> </section> </section> </section> <section id="CD012687-sec-0069"> <h4 class="title">Comparison 2. Wavefront‐optimized versus wavefront‐guided procedures</h4> <section id="CD012687-sec-0070"> <h5 class="title">Proportion of eyes with UCVA of 20/20 or better</h5> <p>Six studies reported data on the proportion of eyes with UCVA of 20/20 or better at six or 12 months after refractive surgery (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). At six months, overall estimates based on data from five studies suggest no evidence for a difference between wavefront‐optimized and wavefront‐guided procedures for eyes with UCVA of 20/20 or better: RR 1.00, 95% CI 0.98 to 1.02; I<sup>2</sup> = 0%; 444 participants. Examining by subgroup, we found similar results in the PRK procedure: RR 0.94, 95% CI 0.87 to 1.02; 1 study, 104 participants; and for LASIK procedure: RR 1.00, 95% CI 0.98 to 1.02, I<sup>2</sup> = 0%; 4 studies, 340 participants) (<a href="./references#CD012687-fig-0018" title="">Analysis 2.1</a>). At 12 months after refractive surgery, the results were no different, as overall estimates from five studies showed no evidence of effect in achieving UCVA of20/20 or better when comparing wavefront‐optimized procedure with wavefront‐guided procedure: RR 1.00, 95% CI 0.99 to 1.02; 5 studies, 618 participants. Results by subgroup also showed no evidence for a difference: studies of PRK: RR 1.02, 95% CI 0.98 to 1.06; I<sup>2</sup> = 0%; 2 studies, 334 participants; and studies of LASIK: RR 1.00, 95% CI 0.98 to 1.02, I<sup>2</sup> = 0%; 3 studies, 284 participants (<a href="./references#CD012687-fig-0019" title="">Analysis 2.2</a>). The certainty of evidence for this outcome at both six and 12 months and by subgroups was low. We downgraded for risk of bias and imprecision. </p> </section> <section id="CD012687-sec-0071"> <h5 class="title">Proportion of eyes without loss of BSCVA</h5> <p>The same six studies above also examined the proportion of eyes without loss of BSCVA at six or 12 months after refractive surgery (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>). At six months, the effect estimates were as follows: overall: RR 0.99, 95% CI 0.94 to 1.04; I<sup>2</sup> = 4%; 4 studies, 258 participants; for PRK procedure: RR 1.00, 95% CI 0.95 to 1.06; 1 study, 104 participants; and LASIK procedure: RR 0.96, 95% CI 0.85 to 1.08; I<sup>2</sup> = 28%; 3 studies, 154 participants (<a href="./references#CD012687-fig-0020" title="">Analysis 2.3</a>). Data were also available for five studies at 12 months, with the following effect estimates: overall: RR 0.99, 95% CI 0.96 to 1.02; I<sup>2</sup> = 0%; 5 studies, 622 participants; PRK procedure: RR 1.01, 95% CI 0.97 to 1.05; I<sup>2</sup> = 0%; 2 studies, 334 participants; and LASIK procedure: RR 0.97, 95% CI 0.94 to 1.01; I<sup>2</sup> = 0%; 3 studies, 288 participants (<a href="./references#CD012687-fig-0021" title="">Analysis 2.4</a>). Evidence at both six and 12 months after refractive surgery and for subgroups of participants in studies of PRK or LASIK suggest no difference between the wavefront‐optimized and corresponding wavefront‐guided procedures (PRK or LASIK) for eyes without loss of BSCVA. We graded the certainty of evidence for this outcome at both time points and by subgroup as low, after downgrading for risk of bias and imprecision. </p> </section> <section id="CD012687-sec-0072"> <h5 class="title">Proportion of eyes within ± 0.5 diopters of target refraction</h5> <p>Data on the proportion of eyes within ± 0.5 diopters of target refraction six or 12 months after refractive surgery were available for four studies at six months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>) and at 12 months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>). The effect estimates at six months were: overall: RR 0.93, 95% CI 0.87 to 1.00; I<sup>2</sup> = 0%; 4 studies, 258 participants; PRK procedure: RR 0.94, 95% CI 0.86 to 1.03; 1 study, 104 participants; and LASIK procedure: RR 0.92, 95% CI 0.81 to 1.04; I<sup>2</sup> = 8%; 3 studies, 154 participants (<a href="./references#CD012687-fig-0022" title="">Analysis 2.5</a>). For this outcome at 12 months, the overall effect estimate was: RR 1.02, 95% CI 0.95 to 1.09; I<sup>2</sup> = 33%; 4 studies, 480 participants. Examining by subgroups, the estimates were: PRK procedure: RR 1.06, 95% CI 0.97 to 1.15; 1 study, 192 participants; and LASIK procedure: RR 0.97, 95% CI 0.86 to 1.11; I<sup>2</sup> = 47%; 3 studies, 288 participants (<a href="./references#CD012687-fig-0023" title="">Analysis 2.6</a>). Therefore neither at six nor 12 at months after surgery was there any evidence for a difference betweenthewavefront‐optimized and wavefront‐guided procedures. The certainty of evidence was low. We downgraded for risk of bias and imprecision. </p> </section> <section id="CD012687-sec-0073"> <h5 class="title">Mean refractive error, spherical equivalent</h5> <p>Data for this outcome at six months were available from four studies (<a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) and at 12 months from six studies (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0003" title="RyanDS , SiaRK , RabinJ , RiversBA , StutzmanRD , PasternakJF , et al. Contrast sensitivity after wavefront-guided and wavefront-optimized PRK and LASIK for myopia and myopic astigmatism. Journal of Refractive Surgery2018;34(9):590-6. [DOI: 10.3928/1081597X-20180716-01]">Bower 2018</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>). We did not calculate an overall effect estimate at six months, owing to statistical heterogeneity between subgroups (I<sup>2</sup> = 69%). However, the estimated mean differences in refractive error by type of procedure were as follows: PRK: MD 0.09, 95% CI −0.02 to 0.20; 1 study, 138 participants; and for LASIK: MD −0.12, 95% CI −0.19 to −0.05; I<sup>2</sup> = 0%; 3 studies, 280 participants ( <a href="./references#CD012687-fig-0024" title="">Analysis 2.7</a>). The certainty of evidence for this outcome was low for estimates from studies of PRK, after downgrading for risk of bias and imprecision, and moderate for LASIK procedures, downgrading for risk of bias. </p> <p>Due to substantial statistical heterogeneity, we did not calculate an overall effect estimate at 12 months. While effect estimates from two studies suggest no evidence for a difference between wavefront‐optimized and wavefront‐guided PRK procedures at 12 months (MD 0.07, 95% CI −0.03 to 0.18; I<sup>2</sup> = 50%; 334 participants; low certainty of evidence), data from four studies of LASIK suggest a probable benefit in favor of wavefront‐optimized LASIK: MD −0.14, 95% CI −0.19 to −0.09; I<sup>2</sup> = 0%; 472 participants (<a href="./references#CD012687-fig-0025" title="">Analysis 2.8</a>). The certainty of evidence was moderate. We downgraded only for risk of bias. </p> </section> <section id="CD012687-sec-0074"> <h5 class="title">Higher<i>‐</i>order aberrations (HOAs) post‐treatment </h5> <p>Mean HOAs post‐surgery were reported in five studies at one month (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>), in seven studies at three months (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0021" title="MiraftabM , SeyedianMA , HashemiH . Wavefront-guided vs wavefront-optimized LASIK: a randomized clinical trial comparing contralateral eyes. Journal of Refractive Surgery2011;27(4):245-50. [DOI: 10.3928/1081597X-20100812-02]">Miraftab 2011</a>; <a href="./references#CD012687-bbs2-0022" title="MoshirfarM , ChurginDS , BettsBS , HsuM , SikderS , NeufferM , et al. Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations. Clinical Ophthalmology2011;5:1185-93. [DOI: https://dx.doi.org/10.2147/OPTH.S24319]">Moshirfar 2011a</a>; <a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>), in five studies at six months (<a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>; <a href="./references#CD012687-bbs2-0033" title="ZhaoXB , LiKJ , ZhaoZH , JiaZY . Comparison the effectiveness of wavefront-guided and wavefront-optimized LASIK for myopia and myopic astigmatism. International Eye Science2015;15(12):2130-3. [DOI: 10.3980/j.issn.1672-5123.2015.12.28]">Zhao 2015</a>) and in five studies at 12 months (<a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>; <a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>; <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>). </p> <p>We estimated mean HOAs from meta‐analysis of findings from these studies by post‐surgery times. </p> <section id="CD012687-sec-0075"> <h6 class="title">One month:</h6> <p>We did not calculate overall effect estimates due to substantial statistical heterogeneity from four studies of LASIK (I<sup>2</sup> = 92%).The effect estimate for PRK procedure was: MD 0.03, 95% CI −0.03 to 0.09; 1 study, 140 participants) (<a href="./references#CD012687-fig-0026" title="">Analysis 2.9</a>). For studies of LASIK (4 studies, 326 participants), point estimates from three of the four studies showed no difference between the two groups. The estimate in <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a> differs in direction from those of the other three estimates and suggests a benefit for this outcome in favor of wavefront‐guided procedure. <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a> enrolled both eyes of participants, but reported insufficient methodologic details to explain the discrepancy observed. Excluding <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a> eliminated the substantial statistical heterogeneity among the studies of LASIK (I<sup>2</sup> = 92%). Estimates from the remaining three studies of LASIK showed no evidence of benefit: MD 0.03, 95% CI −0.01 to 0.07; I<sup>2</sup> = 0%; 3 studies, 296 participants (<a href="./references#CD012687-fig-0026" title="">Analysis 2.9</a>). The effect estimates by each type of procedure (PRK or LASIK) suggest no evidence for a difference in HOAs at one month. We graded the certainty of evidence as very low, downgrading for risk of bias, inconsistency and imprecision. </p> </section> <section id="CD012687-sec-0076"> <h6 class="title">Three month<i>s</i>: </h6> <p>We calculated no overall estimates due to substantial statistical heterogeneity among five studies of LASIK. </p> <p>Estimates from studies of PRK (MD 0.06, 95% CI 0.01 to 0.11; I<sup>2</sup> = 0%; 2 studies, 182 participants) (<a href="./references#CD012687-fig-0027" title="">Analysis 2.10</a>), support a small but clinically insignificant benefit for wavefront‐guided PRK, with low certainty of evidence. We downgraded for risk of bias and imprecision. </p> <p>As with the estimates at one month, by excluding <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>, which was responsible for the substantial statistical heterogeneity observed among the studies of LASIK (I<sup>2</sup> = 93%), the estimates from the remaining four studies of LASIK showed no evidence of benefit: MD −0.01, 95% CI −0.06 to 0.04; I<sup>2</sup> = 41%; 4 studies, 318 participants) (<a href="./references#CD012687-fig-0027" title="">Analysis 2.10</a>). We graded the certainty of evidence as very low, downgraded for risk of bias, inconsistency and imprecision. </p> </section> <section id="CD012687-sec-0077"> <h6 class="title">Six months:</h6> <p>We calculated effect estimates of HOAs at six months as follows: overall: MD 0.03, 95% CI 0.00 to 0.06; I<sup>2</sup> = 0%; 5 studies, 478 participants; for PRK: MD 0.06, 95% CI −0.01 to 0.13; 1 study, 138 participants; and for LASIK: MD 0.03, 95% CI −0.01 to 0.06; I<sup>2</sup> = 0%; 4 studies, 340 participants) (<a href="./references#CD012687-fig-0028" title="">Analysis 2.11</a>). </p> </section> <section id="CD012687-sec-0078"> <h6 class="title">12 months:</h6> <p>At 12 months, the effect estimates are: overall: MD 0.03, 95% CI −0.01 to 0.07; I<sup>2</sup> = 41%; 5 studies, 622 participants; for PRK procedure: MD 0.02, 95% CI −0.08 to 0.13; I<sup>2</sup> = 82%; 2 studies, 334 participants; and for LASIK: MD 0.03, 95% CI −0.01 to 0.06; I<sup>2</sup> = 0%; 4 studies, 288 participants (<a href="./references#CD012687-fig-0029" title="">Analysis 2.12</a>). </p> <p>We graded the certainty of evidence for this outcome at six and 12 months, overall and by subgroup, as low, downgrading for risk of bias and imprecision. </p> </section> </section> </section> <section id="CD012687-sec-0079"> <h4 class="title">Comparison 3. Wavefront‐guided LASIK versus wavefront‐guided PRK</h4> <p>Only one study (<a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a>) examined this comparison and reported 1‐, 3‐, 6‐ or 12‐month data for the outcomes of interest. </p> <section id="CD012687-sec-0080"> <h5 class="title">Proportion of eyes with UCVA of 20/20 or better</h5> <p>Point estimates at six months and 12 months were the same: RR 1.03, 95% CI 0.93 to 1.15; 66 participants) and provided no evidence for a difference between wavefront‐guided LASIK and wavefront‐guided PRK for eyes with UCVA of 20/20 or better (<a href="./references#CD012687-fig-0030" title="">Analysis 3.1</a>). </p> </section> <section id="CD012687-sec-0081"> <h5 class="title">Proportion of eyes without loss of BSCVA</h5> <p><a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a> did not report data for this outcome at six months. The effect estimate at 12 months after surgery suggested no any difference between wavefront‐guided LASIK and PRK for eyes without loss of BSCVA: RR 1.03, 95% CI 0.93 to 1.15; 66 participants, or preserving pre‐surgery BSCVA (<a href="./references#CD012687-fig-0031" title="">Analysis 3.2</a>). </p> </section> <section id="CD012687-sec-0082"> <h5 class="title">Proportion of eyes within ± 0.5 diopters of target refraction</h5> <p>Point estimates for this outcome at six months (RR 1.00, 95% CI 0.92 to 1.09; 66 participants) and at 12 months (RR 0.97, 95% CI 0.82 to 1.14; 66 participants) indicate no evidence for a difference between the two wavefront‐guided procedures for achieving post‐operative refractive errors within ± 0.5 diopters of target refraction (<a href="./references#CD012687-fig-0032" title="">Analysis 3.3</a>). </p> </section> <section id="CD012687-sec-0083"> <h5 class="title">Mean refractive error, spherical equivalent</h5> <p>Neither at six months (MD 0.00, 95% CI −0.13 to 0.13; 66 participants) nor at 12 months (MD 0.01, 95% CI −0.18 to 0.20; 66 participants) do the effect estimates suggest any evidence for a difference betweenwavefront‐guided LASIK and wavefront‐guided PRK in mean refractive error after surgery (<a href="./references#CD012687-fig-0033" title="">Analysis 3.4</a>). </p> </section> <section id="CD012687-sec-0084"> <h5 class="title">Higher order aberrations (HOAs) post‐treatment</h5> <p>Point estimates for mean HOAs based on data for 66 participants consistently show no evidence for a difference between wavefront‐guided LASIK and wavefront‐guided PRK: one month post‐surgery: MD −0.06, 95% CI −0.15 to 0.03; at three months: MD 0.00, 95% CI −0.07 to 0.07; at six months: MD 0.02, 95% CI −0.05 to 0.09; and at 12 months: MD −0.01, 95% CI −0.09 to 0.07) after refractive surgery (<a href="./references#CD012687-fig-0034" title="">Analysis 3.5</a>). </p> <p>The certainty of evidence for all the outcomes examined when wavefront‐guided LASIK was compared with wavefront‐guided PRK was very low, owing to risk of bias and serious imprecision. </p> </section> </section> <section id="CD012687-sec-0085"> <h4 class="title">Adverse events/effects</h4> <p>Only one study reported information on eyes that lost more than two lines of BSCVA in either group (<a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>). The investigators only reported that "the frequencies with which the groups maintained their preoperative corrected distance visual acuity (CDVA), lost 1 or 2 or more lines, or gained 1 or 2 or more lines after undergoing LASIK were not statistically different from each other (all P&gt;0.05)" </p> <p>In <a href="./references#CD012687-bbs2-0002" title="RiversB , RyanDS , SiaRK , PeppersL , LoganLA , EaddyJB , et al. Visual performance after wavefront-guided and wavefront-optimized photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1525. RyanDS , SiaRK , DeaverDM , MaurerT , HowellCL , LoganLA , et al. Visual outcomes and the identification of static and dynamic targets of military interest after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive Keratectomy (PRK). Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1522. RyanDS , SiaRK , PeppersL , EaddyJB , StutzmanRD , PasternakJ , et al, . Visual performance of U.S military service members (USM) in identification of infrared targets after wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4861. RyanDS , SiaRK , StutzmanRD , PasternakJF , HowardRS , HowellCL . Wavefront-guided versus wavefront-optimized photorefractive keratectomy: visual and military task performance. Military Medicine2017;182(1):e1636-e44. [DOI: dx.doi.org/10.7205/MILMED-D-15-00576]SiaRK , PeppersL , RyanDS , StutzmanR , PasternakJF , EaddyJB , et al. Corneal aberrations and its effect on contrast sensitivity after wavefront-guided and wavefront-optimized refractive surgeries. Investigative Ophthalmology and Visual Science2015;56(7):ARVO E-abstract 3915. SiaRK , RyanDS , PeppersL , LoganL , PasternakJ , StutzmanRD , et al. Target detection in infrared images after wavefront-guided and wavefront optimized PRK and LASIK. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 4860. SiaRK , RyanDS , StutzmanRD , PasternakJF , EaddyJB , LoganLA , et al. Wavefront-guided versus wavefront-optimized photorefractive keratectomy: clinical outcomes and patient satisfaction. Journal of Cataract and Refractive Surgery2015;41(10):2152-64. [DOI: 10.1016/j.jcrs.2015.10.054]StutzmanR , SiaRK , RyanDS , MaurerT , HowellCL , EaddyJB , et al. The effect of wavefront-guided (WFG) and wavefront-optimized (WFO) photorefractive keratectomy (PRK) on subjective quality of vision (QOV) and military task performance (MTP) among active Duty U.S. soldiers. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 1523. ">Bower 2015</a>, dry eye was the most common complication after each type of treatment, with no difference in frequency between wavefront‐optimized and wavefront‐guided PRK at six (P = 0.58) or at 12 months (P = 0.17) after surgery. Investigators observed delayed epithelial healing and early corneal haze in both intervention groups. “Clinically significant haze (grade ≥2) was observed in 7 (6.5%) participants in the wavefront‐guided eyes and in 3 (2.9%) wavefront‐optimized eyes at 1 month and in 1 (1.1%) wavefront‐guided eye versus 3 (3.3%) wavefront‐optimized eyes at 3 months postoperatively”. All participants with clinically significant haze were treated with topical steroids and required no mechanical debridement or phototherapeutic keratectomy. </p> <p>In <a href="./references#CD012687-bbs2-0012" title="LeeHK , ChoeCM , MaKT , KimEK . Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery. Journal of Refractive Surgery2006;22(7):647-55. ">Lee 2006</a>, investigators reported that both wavefront‐guided and conventional LASIK had similar preoperative subjective visual symptom scores (P = 0.48), all graded as 0 or 1, with visual symptom scores higher for both groups postoperatively. The mean subjective symptom score was highest at one month postoperatively and decreased over six months. Glare score of &gt; 3 was recorded in 12 (15.4%) conventional LASIK eyes compared to only seven (8.6%) wavefront‐guided LASIK eyes at six months postoperatively (P = 0.012). Participants reported that glare or halo interfered with their daily living. </p> <p><a href="./references#CD012687-bbs2-0014" title="MancheEE , HawWW . Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society2011;109:201-20. ">Manche 2011</a> reported "no incidence of corneal haze in the wavefront‐guided PRK group compared to the wavefront‐guided LASIK. No eyes were re‐treated within the first 12 months." <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a> reported "no difference between the wavefront‐optimized and wavefront‐guided LASIK groups for subjective parameters such as day and night clarity".<br/>In <a href="./references#CD012687-bbs2-0017" title="HeL , MancheEE . Contralateral eye-to-eye comparison of wavefront-guided and wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA Ophthalmology2015;133(1):51-9. [DOI: 10.1001/jamaophthalmol.2014.3876]HeL , MancheEE . Prospective randomized contralateral eye evaluation of subjective quality of vision after wavefront-guided or wavefront- optimized photorefractive keratectomy. Journal of Refractive Surgery2014;30(1):6-12. SmithR , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized photorefractive keratectomy: a prospective randomized contralateral eye study. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 5977. SmithR , MancheEE . Three-month outcomes from a prospective, randomized, contralateral, eye-to-eye comparison of wavefront-guided and wavefront-optimized PRK in myopes. Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 5283. ToyBC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a randomized fellow eye comparison of photorefractive keratectomy using 2 excimer laser platforms. Eye and Contact Lens2018;44(Suppl 1):S71-6. [DOI: 10.1097/ICL.0000000000000332]">Manche 2015</a>, investigators reported that at 12 months "participants in the wavefront‐optimized PRK group had fewer problems with clarity during the day (P = .035) and at night (0.040) with fewer visual symptoms (P = .039)". </p> <p><a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a> reported no complications in either the wavefront‐guided or conventional PRK group; safety (gain or loss of corrected distance visual acuity) was similar between groups. </p> <p><a href="./references#CD012687-bbs2-0023" title="MoshirfarM , BettsBS , ChurginDS , HsuM , NeufferM , SikderS , et al. A prospective, randomized, fellow eye comparison of Wavelight Allegretto wave eye-Q versus VISX CustomVue STAR S4 IR; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations. Clinical Ophthalmology2011;5:1339-47. ">Moshirfar 2011b</a>, reported that "one eye in the wavefront‐optimized LASIK group gained two lines, and one eye lost one line of corrected distance visual acuity in each group". “In the wavefront‐optimized LASIK group, the loss of vision was from residual astigmatism due to a central island. In the wavefront‐guided LASIK group, the loss was due to irregular corneal epithelium secondary to superficial punctate keratopathy. Investigators reported that no other eye in the study population lost any lines of corrected distance visual acuity". </p> <p><a href="./references#CD012687-bbs2-0032" title="YuJ , ChenH , WangF . Patient satisfaction and visual symptoms after wavefront-guided and wavefront-optimized LASIK with the WaveLight platform. Journal of Refractive Surgery2008;24(5):477-86. [DOI: 10.3928/1081597X-20080501-05]">Yu 2008a</a> reported that most of the symptoms were often “mild,” and did not differ between the wavefront‐guided and conventional LASIK groups. </p> </section> <section id="CD012687-sec-0086"> <h4 class="title">Subgroup analysis</h4> <p>We had planned to perform subgroup analysis according to ranges of myopia: low to moderate myopia (&lt; −0.50 to −6.00 D) and moderate to high myopia (&lt; −6.00 to −15.00 D). We did not undertake this analysis due to insufficient data. However, we performed subgroup analysis by further stratifying data according to the method for creating corneal flap (PRK or LASIK). The test for subgroup differences indicated no statistically significant subgroup effect (data not shown), suggesting that with neither PRK nor LASIK is a wavefront procedure superior to the corresponding conventional procedure, nor are wavefront‐optimized procedures superior to wavefront‐guided procedures for the outcomes assessed in this review. </p> </section> <section id="CD012687-sec-0087"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the impact of excluding studies with inconsistent direct estimates of effects (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>) compared to other studies or studies conducted among participants with hyperopia (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0016" title="SalesCS , MancheEE . One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes. Clinical Ophthalmology2014;8:2229-38. [PMID: 25419115]">Manche 2014</a>) on the effect estimates for which these studies contributed data. We found no impact of excluding the latter two studies on the effect estimates (data not shown). </p> <p>Three studies (<a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a>; <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a>; <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a>) were industry‐funded. We did not include <a href="./references#CD012687-bbs2-0004" title="BrintSF . Higher order aberrations after LASIK for myopia with alcon and wavelight lasers: a prospective randomized trial. Journal of Refractive Surgery2005;21(6):S799-803. ">Brint 2005</a> in the meta‐analysis because it appeared to be responsible for considerable heterogeneity. <a href="./references#CD012687-bbs2-0013" title="LeeWS , MancheEE . Comparison of simulated keratometric changes following wavefront-guided and wavefront-optimized myopic laser-assisted in situ keratomileusis. Clinical Ophthalmology2018;12:613-9. [DOI: 10.2147/OPTH.S161387]">Lee 2018</a> did not contribute data to the effect estimates. <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a> was the only industry‐funded study that contributed data for the comparison between wavefront‐optimized and wavefront‐guided procedures, and provided data for the following outcomes at six and at 12 months: UCVA of 20/20, eyes within ± 0.50 D of target refraction, mean refractive error expressed as mean spherical and BSCVA at 12 months. <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a> also provided data for mean HOAs at 1, 3, 6 and at 12 months. Excluding <a href="./references#CD012687-bbs2-0028" title="RoeJR , MancheEE . Prospective, randomized, contralateral eye comparison of wavefront-guided and wavefront-optimized laser in situ keratomileusis. American Journal of Ophthalmology2019;207:175-83. [DOI: dx.doi.org/10.1016/j.ajo.2019.05.026]">Roe 2019</a> from the analysis produced no change in the effect for any of these outcomes (data not shown). </p> <p>Post hoc, we had also planned to assess the impact of restricting the analysis to studies that analyzed data at the participant level. However, only three studies took this approach (<a href="./references#CD012687-bbs2-0008" title="DurrieDS , SmithRT , WaringGO , StahlJE , SchwendemanFJ . Comparing conventional and wavefront-optimized LASIK for the treatment of hyperopia. Journal of Refractive Surgery2010;26(5):356-63. [DOI: 10.3928/1081597X-20090617-07]">Durrie 2010</a>; <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a>; <a href="./references#CD012687-bbs2-0027" title="QiuP , WangZ , YangB , HuangGF , XiaoBY , GuJJ , et al. The analysis of subjective evaluation and contrast sensitivity function after wavefront-guided laser in situ keratomileusis and traditional laser in situ keratomileusis. Chinese Journal of Ophthalmology2007;43(4):329-35. ">Qiu 2007</a>). Of the remaining 30 studies, in which both eyes of each participant were randomized to the same intervention group or two eyes of participants are in different intervention groups, only one study reported having accounted for non‐independence in their analysis (<a href="./references#CD012687-bbs2-0020" title="MifflinMD , HatchBB , SikderS , BellJ , KurzCJ , MoshirfarM . Custom vs conventional PRK: a prospective, randomized, contralateral eye comparison of postoperative visual function. Journal of Refractive Surgery2012;28(2):127-32. [DOI: 10.3928/1081597X-20120103-01]">Mifflin 2012</a>). No sensitivity analysis based on design was therefore possible. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012687-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012687-sec-0088"></div> <section id="CD012687-sec-0089"> <h3 class="title" id="CD012687-sec-0089">Summary of main results</h3> <p>We identified 33 randomized controlled trials (RCTs) that had enrolled 1499 participants (2797 eyes) aged 18 years and older, with refractive errors ranging from high myopia to low hyperopia, who underwent wavefront modified or conventional excimer laser (PRK, LASIK or LASEK) refractive surgery. Our findings from analyses of the available evidence for outcomes examined at 12 months are shown in the <a href="./full#CD012687-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD012687-tbl-0002">summary of findings Table 2</a>, and <a href="./full#CD012687-tbl-0003">summary of findings Table 3</a> for the main comparisons. Evidence for six‐month outcomes are shown in additional <a href="#CD012687-tbl-0004">Table 1</a>, <a href="#CD012687-tbl-0005">Table 2</a>, and <a href="#CD012687-tbl-0006">Table 3</a>. </p> <div class="table" id="CD012687-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Wavefront compared to conventional procedure for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront compared to conventional procedure for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront procedure<br/><b>Comparison:</b> Conventional procedure </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Conventional procedure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months ‐ overall estimate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831 per 1000<br/>(798 to 856) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.96 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment: 6 months ‐ overall estimate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/>(172 to 272) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/>(0.93 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/>(715 to 926) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.78 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 per 1000<br/>(765 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/>(0.85 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure PRK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/>(0.09 lower to 0.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure LASIK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 higher<br/>(0.05 lower to 0.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: PRK procedure: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies reported data on PRK. Due to substantial heterogeneity, we did not combine data in a meta‐analysis. Point estimates from <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a> (MD = −0.21, 95% CI −0.26 to −0.16) suggest benefit in favor of wavefront‐guided PRK relative to conventional PRK (56 eyes of 56 participants). Estimates from <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a> (MD 0.17, 95% CI 0.02 to 0.32) favors conventional PRK (56 eyes, 28 participants). There were no data on LASIK for this outcome at 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 2.4.1 </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for imprecision.<br/><sup>c</sup>Downgraded for inconsistency. </p> </div> </div> <div class="table" id="CD012687-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Wavefront‐optimized compared to wavefront‐guided for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐optimized compared to wavefront‐guided for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐optimized<br/><b>Comparison:</b> Wavefront‐guided </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐optimized</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>982 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>982 per 1000<br/>(962 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.98 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>444<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/>(51 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.94 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>938 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872 per 1000<br/>(816 to 938) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.87 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure PRK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 higher<br/>(0.02 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure LASIK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 lower<br/>(0.19 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean HOAs post‐treatment, measured by machine with wavefront sensor: 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0 to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA) and proportion of eyes with optical side effects, such as glare and halo: 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These two outcomes were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for imprecision. </p> </div> </div> <div class="table" id="CD012687-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐guided LASIK<br/><b>Comparison:</b> Wavefront‐guided PRK </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided PRK</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided LASIK</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>939 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>968 per 1000<br/>(874 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 per 1000<br/>(892 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.92 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0.13 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 higher<br/>(0.05 lower to 0.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with optical side effects, such as glare and halo: 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for very serious imprecision (‐2). </p> </div> </div> <p>There was no evidence of a difference in the primary visual acuity outcomes including proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better or the proportion of eyes without loss of one or more lines of best spectacle‐corrected visual acuity (BSCVA) at six and 12 months post‐treatment when wavefront refractive surgery procedures were compared with the corresponding conventional procedure or when wavefront‐optimized was compared with wavefront‐guided procedures. We also found no evidence of a difference in the proportion of eyes within ± 0.50 D of target refraction or mean refractive error at six and 12 months post‐treatment. </p> <p>However, the available evidence suggests that wavefront‐modified PRK, LASIK or LASEK, compared to their conventional counterparts, may lead to improvement in higher‐order aberrations (HOAs) at one and three months after refractive surgery but not at six or 12 months. In addition, evidence supports probable improvement in mean refractive error (spherical equivalent) in favor of wavefront‐optimized LASIK compared to wavefront‐guided LASIK at both six and 12 months after refractive surgery. There is no evidence that the comparison between wavefront‐optimized PRK or LASIK or the corresponding wavefront‐guided PRK or LASIK had any effect on higher‐order aberrations (HOAs) at any of the time points for which we found data. </p> <p>Information on adverse effects were infrequently reported from individual studies. Only one study reported information on eyes that had lost more than two lines of BSCVA; the investigators concluded that there were no differences between groups. For studies that reported optical side effects such as glare and halo, investigators found no evidence for a difference between groups. The safety of these procedures therefore appears to be comparable. Overall, wavefront or conventional (PRK or LASIK) refractive surgery procedures showed comparable effectiveness for the treatment of refractive errors in adults. Some statistically significant differences, such as mean refractive error and HOAs, were small and clinically unimportant, and were inconsistent at different time points. </p> </section> <section id="CD012687-sec-0090"> <h3 class="title" id="CD012687-sec-0090">Overall completeness and applicability of evidence</h3> <p>We included only RCTs in this review. The studies varied in a number of characteristics. Although the studies had enrolled participants with refractive errors ranging from low hyperopia to high myopia, most of them were conducted among participants with low to moderate myopia. Only two studies included participants with low hyperopia and another two included participants with mean refractive errors at values consistent with high myopia. Findings from this review are therefore most applicable to people with low to moderate myopia, and should be applied with caution to people with high myopia or with moderate or high hyperopia. Primary studies were mostly conducted in the USA, Europe and Asia; most of the participants were women. Investigators typically had excluded candidates for refractive surgery who had other ocular pathologies or systemic comorbidities. Hence the evidence from this review may not be applicable to all men and to people of non‐European and non‐Asian ancestry. </p> </section> <section id="CD012687-sec-0091"> <h3 class="title" id="CD012687-sec-0091">Quality of the evidence</h3> <p>We elected to include outcome data only from RCTs. Potentially includable studies were reviewed by at least two review authors according to Cochrane's established methods. The quality of reporting on methods used in individual trials was almost uniformly poor, with most factors evaluated for potential risk of bias not mentioned in reports from most trials. Such incomplete reporting indicates a failure to comply with CONSORT guidelines (<a href="./references#CD012687-bbs2-0086" title="AltmanDG , MoherD , SchultzKF . Improving the reporting of randomised trials: The CONSORT statement and beyond. Statistics in Medicine2012;31(25):2985-97.">Altman 2012</a>). No trial report included a CONSORT diagram, whether due to the preference of the authors of the trial reports or to editorial policy. Certainty of evidence for the outcomes assessed was mostly low to very low, owing to risks of bias, inconsistency and imprecision. For most studies, the method of random sequence generation or method of concealing treatment allocation was not reported. Risks of performance, detection, attrition bias and selective outcome reporting were unclear for most studies. Wide confidence intervals for effect estimates were a limitation on the quality of the evidence and warranted a further downgrade of the certainty of evidence for imprecision. </p> </section> <section id="CD012687-sec-0092"> <h3 class="title" id="CD012687-sec-0092">Potential biases in the review process</h3> <p>For this review, we followed standard Cochrane review methods. We performed a comprehensive search of electronic bibliographic databases for studies, without imposing publication date or language restrictions, and also searched references and citations for studies potentially not identified by our search strategies to minimize the potential for bias in study selection. We did not include non‐randomized studies due to high risk of bias. Among studies that used a paired‐eye design or that assigned the same intervention to both eyes, none of them reported having corrected the analysis for correlations of outcomes between the two eyes of the same participant. Failure to account for correlation between eyes may lead to incorrect estimation of an intervention effect with a false increase in precision (<a href="./references#CD012687-bbs2-0109" title="MurdochI . People and eyes: statistics in ophthalmology. Community Eye Health1998;11(27):43. [PMID: 17492040]">Murdoch 1998</a>). The precision of the effect estimates as represented by the confidence intervals is therefore uncertain. We found a few controlled clinical trials (CCTs) in our searches. These had used alternation, record numbers, and other means of assigning intervention. Authors of updates may wish to include CCTs in separate or combined analyses. Most included studies were small; six of the 33 enrolled fewer than 20 eyes per study group. Sometimes even the larger trials had insufficient power to rule out clinically meaningful differences between groups for the outcomes compared. We sought information about financial support of studies as a potential source of bias. Investigators of most studies did not report any source of funding. Two studies were US government‐funded; three studies were funded by manufacturers of one of the devices under investigation, and some study investigators had financial relationships with industry sponsors that marketed study devices. </p> </section> <section id="CD012687-sec-0093"> <h3 class="title" id="CD012687-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this review are consistent with previous reviews. Although wavefront‐optimized or ‐guided refractive surgery have had technological improvements compared with conventional refractive surgery, wavefront‐modified ablation profiles have not demonstrated superiority in terms of uncorrected visual acuity, visual loss and residual refractive errors (<a href="./references#CD012687-bbs2-0091" title="FaresU , SulemanH , Al-AqabaMA , OtriAM , SaidDG , DuaHS . Efficacy, predictability, and safety of wavefront-guided refractive laser treatment: metaanalysis. Journal of Cataract and Refractive Surgery2011;37(8):1465-75.">Fares 2011</a>; <a href="./references#CD012687-bbs2-0092" title="FengY , YuJ , WangQ . Meta-analysis of wavefront-guided vs. wavefront-optimized LASIK for myopia. Optometry and Vision Science2011;88(12):1463-9.">Feng 2011</a>; <a href="./references#CD012687-bbs2-0100" title="KobashiH , KamiyaK , HoshiK , IgarashiA , ShimizuK . Wavefront-guided versus non-wavefront-guided photorefractive keratectomy for myopia: meta-analysis of randomized controlled trials. PLOS One2014;9(7):e103605.">Kobashi 2014</a>; <a href="./references#CD012687-bbs2-0117" title="SmadjaD , Reggiani-MelloG , SanthiagoMR , KruegerRR . Wavefront ablation profiles in refractive surgery: description, results, and limitations. Journal of Refractive Surgery2012;28(3):224-32.">Smadja 2012</a>). Some authors have concluded that wavefront‐guided LASIK is superior for treating highly aberrant corneas relative to other modalities (<a href="./references#CD012687-bbs2-0092" title="FengY , YuJ , WangQ . Meta-analysis of wavefront-guided vs. wavefront-optimized LASIK for myopia. Optometry and Vision Science2011;88(12):1463-9.">Feng 2011</a>; <a href="./references#CD012687-bbs2-0107" title="MancheE , RoeJ . Recent advances in wavefront-guided LASIK. Current Opinion in Ophthalmology2018;29(4):286-91.">Manche 2018</a>). We also found in this review that wavefront‐guided LASIK achieved smaller HOAs compared with conventional LASIK, although not consistently over time. Consistent with a previous review (<a href="./references#CD012687-bbs2-0099" title="KimA , ChuckRS . Wavefront-guided customized corneal ablation. Current Opinion in Ophthalmology2008;19(4):314-20.">Kim 2008</a>), we also found that compared to conventional treatments, wavefront‐modified ablation achieved smaller HOAs after surgery </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012687-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012687-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012687-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012687-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months." data-id="CD012687-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months." data-id="CD012687-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months." data-id="CD012687-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Wavefront vs Conventional procedure, outcome: 1.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months" data-id="CD012687-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 2: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months" data-id="CD012687-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 2: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 3: Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months" data-id="CD012687-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 3: Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 4: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months" data-id="CD012687-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 4: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 5: Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months" data-id="CD012687-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 5: Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 6: Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months" data-id="CD012687-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 6: Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 7: Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months" data-id="CD012687-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 7: Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 8: Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months" data-id="CD012687-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 8: Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 9: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month" data-id="CD012687-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 9: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 10: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months" data-id="CD012687-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 10: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Wavefront vs Conventional procedure, Outcome 11: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months" data-id="CD012687-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Wavefront vs Conventional procedure, Outcome 11: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months" data-id="CD012687-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 2: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months" data-id="CD012687-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 2: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 3: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months" data-id="CD012687-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 3: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 4: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months." data-id="CD012687-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 4: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 5: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment: 6 months" data-id="CD012687-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 5: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 6: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment:12 months" data-id="CD012687-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 6: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 7: Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months." data-id="CD012687-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 7: Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 8: Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months" data-id="CD012687-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 8: Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 9: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month" data-id="CD012687-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 9: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 10: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months" data-id="CD012687-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 10: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 11: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months" data-id="CD012687-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 11: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 12: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 12 months" data-id="CD012687-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Wavefront‐optimized vs Wavefront‐guided, Outcome 12: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment." data-id="CD012687-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 1: Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 2: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment." data-id="CD012687-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 2: Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 3: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment." data-id="CD012687-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 3: Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 4: Mean refractive error expressed as mean spherical equivalent post‐treatment." data-id="CD012687-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 4: Mean refractive error expressed as mean spherical equivalent post‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012687-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/urn:x-wiley:14651858:media:CD012687:CD012687-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 5: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor" data-id="CD012687-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_t/tCD012687-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Wavefront‐guided LASIK vs Wavefront‐guided PRK, Outcome 5: Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/media/CDSR/CD012687/image_n/nCD012687-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012687-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Wavefront procedures compared to conventional procedures for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront procedures compared to conventional procedures for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront procedures<br/><b>Comparison:</b> Conventional procedures </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with conventional procedure</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ Procedure: PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 100<br/>(74 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.86 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ Procedure: LASIK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There are no data on LASIK for this outcome at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(5 to 6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/>(0.81 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 100<br/>(74 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.86 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure LASIK </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There are no data on LASIK for this outcome at 12 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK was ‐0.114 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 higher<br/>(0.11 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment‐procedure LASIK; Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor; proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA); proportion of eyes with optical side effects, such as glare and halo:12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no data on these outcomes at 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded forImprecision.<br/><sup>b</sup>Downgraded for risk of bias.<br/><sup>c</sup>Downgraded for inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Wavefront procedures compared to conventional procedures for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012687-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐optimized<br/><b>Comparison:</b> Wavefront‐guided procedure </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Any wavefront‐guided procedure</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Any wavefront‐optimized</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(96 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.99 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>618<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(5 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.96 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment:12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 100<br/>(87 to 99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/>(0.95 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure PRK was −0.21 spherical equivalent </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 spherical equivalent higher<br/>(0.03 lower to 0.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure LASIK </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment:12 months ‐ Procedure LASIK ranged from 0.26 spherical equivalent </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.14 spherical equivalent lower<br/>(0.19 lower to 0.09 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 12 months ‐ overall estimate </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 12 months was 0.26 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study that compared wavefront‐optimized LASIK versus wavefront‐guided LASIK reported on loss of 2 or more lines from pretreatment BSCVA that had not returned to baseline by 12 to 24 months after treatment (<a href="./references#CD012687-bbs2-0015" title='HeL , LiuA , MancheEE . Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study. American Journal of Ophthalmology2014;157(6):1170-8.e1. [DOI: 10.1016/j.ajo.2014.02.037]KungJS , MancheEE . Erratum for "Quality of Vision After Wavefront-Guided or Wavefront-Optimized LASIK: A Prospective Randomized Contralateral Eye Study". Journal of refractive surgery (Thorofare, N.J. : 1995)2016;32(12):864. [PMID: 27930801]KungJS , MancheEE . Quality of vision after wavefront-guided or wavefront-optimized LASIK: a prospective randomized contralateral eye study. Journal of Refractive Surgery2016;32(4):230-6. [DOI: 10.3928/1081597X-20151230-01]SalesCS , MancheEE . One-year outcomes from a prospective, randomized, eye-to-eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Ophthalmology2013;120(12):2396-402. [DOI: 10.1016/j.ophtha.2013.05.010]ToyBC , YuC , MancheEE . Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes. Journal of Refractive Surgery2015;31(5):322-7. [DOI: 10.3928/1081597X-20150424-08]'>Manche 2013</a>). Proportion of eyes with optical side effects, such as glare and halo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias. </p> <p><sup>b</sup>Downgraded for imprecision. </p> <p><sup>c</sup>Downgraded for inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Wavefront‐optimized procedures compared to wavefront‐guided procedures for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012687-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐guided LASIK<br/><b>Comparison:</b> Wavefront‐guided PRK </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront‐guided PRK</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with wavefront‐guided LASIK</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 100<br/>(87 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/>(6 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>882 per 1,000<br/>(745 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.82 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 12 months was −0.17 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(0.18 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HOAs post‐treatment, measured by machine with wavefront sensor ‐ 12 months was 0.38 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/>(0.09 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with optical side effects, such as glare and halo: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for serious imprecision (‐2). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012687-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Wavefront compared to conventional procedure for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront compared to conventional procedure for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront procedure<br/><b>Comparison:</b> Conventional procedure </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Conventional procedure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months ‐ overall estimate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831 per 1000<br/>(798 to 856) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.96 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment: 6 months ‐ overall estimate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000<br/>(172 to 272) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/>(0.93 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>917 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/>(715 to 926) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.78 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 per 1000<br/>(765 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/>(0.85 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure PRK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/>(0.09 lower to 0.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months ‐ Procedure LASIK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 higher<br/>(0.05 lower to 0.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: PRK procedure: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies reported data on PRK. Due to substantial heterogeneity, we did not combine data in a meta‐analysis. Point estimates from <a href="./references#CD012687-bbs2-0018" title="MastropasquaL , TotoL , ZuppardiE , NubileM , CarpinetoP , NicolaM , et al. Zyoptix wavefront-guided versus standard photorefractive keratectomy (PRK) in low and moderate myopia: randomized controlled 6-month study. European Journal of Ophthalmology2006;16(2):219-28. ">Mastropasqua 2006</a> (MD = −0.21, 95% CI −0.26 to −0.16) suggest benefit in favor of wavefront‐guided PRK relative to conventional PRK (56 eyes of 56 participants). Estimates from <a href="./references#CD012687-bbs2-0009" title="KarimianF , FeiziS , JafarinasabMR . Conventional versus custom ablation in photorefractive keratectomy: randomized clinical trial. Journal of Cataract and Refractive Surgery2010;36(4):637-43. [DOI: 10.1016/j.jcrs.2009.10.050]">Karimian 2010</a> (MD 0.17, 95% CI 0.02 to 0.32) favors conventional PRK (56 eyes, 28 participants). There were no data on LASIK for this outcome at 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 2.4.1 </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for imprecision.<br/><sup>c</sup>Downgraded for inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Wavefront compared to conventional procedure for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012687-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Wavefront‐optimized compared to wavefront‐guided for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐optimized compared to wavefront‐guided for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐optimized<br/><b>Comparison:</b> Wavefront‐guided </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐optimized</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>982 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>982 per 1000<br/>(962 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.98 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>444<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/>(51 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.94 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>938 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872 per 1000<br/>(816 to 938) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.87 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure PRK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure PRK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 higher<br/>(0.02 lower to 0.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure LASIK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. ‐ Procedure LASIK was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 lower<br/>(0.19 lower to 0.05 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor: 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean HOAs post‐treatment, measured by machine with wavefront sensor: 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0 to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA) and proportion of eyes with optical side effects, such as glare and halo: 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These two outcomes were not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Wavefront‐optimized compared to wavefront‐guided for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012687-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> Adults with refractive errors<br/><b>Setting:</b> Eye hospital<br/><b>Intervention:</b> Wavefront‐guided LASIK<br/><b>Comparison:</b> Wavefront‐guided PRK </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided PRK</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Wavefront‐guided LASIK</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>939 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>968 per 1000<br/>(874 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.93 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 per 1000<br/>(892 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.92 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean refractive error expressed as mean spherical equivalent post‐treatment. ‐ 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0.13 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 6 months was 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 higher<br/>(0.05 lower to 0.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of eyes with optical side effects, such as glare and halo: 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean Difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias.<br/><sup>b</sup>Downgraded for very serious imprecision (‐2). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Wavefront‐guided LASIK compared to wavefront‐guided PRK for adults with refractive errors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/full#CD012687-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012687-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Wavefront vs Conventional procedure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Procedure: PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.88, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.85, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.09, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.05, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.11, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.11, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.22, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Procedure LASEK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.38, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Procedure PRK: 3 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.10, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Procedure LASIK: 3 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.04, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Procedure LASEK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.26, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Procedure PRK: 6 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Wavefront vs Conventional procedure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012687-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Wavefront‐optimized vs Wavefront‐guided</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.99, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.94, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.97, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.94, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.97, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Mean refractive error expressed as mean spherical equivalent post‐treatment: 6 months. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.02, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.19, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Mean refractive error expressed as mean spherical equivalent post‐treatment:12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.03, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.19, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.03, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.06, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.01, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Procedure PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Procedure LASIK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Wavefront‐optimized vs Wavefront‐guided</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012687-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Wavefront‐guided LASIK vs Wavefront‐guided PRK</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Proportion of eyes without loss of 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Proportion of eyes within ± 0.50 diopters (D) of target refraction post‐treatment. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.82, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mean refractive error expressed as mean spherical equivalent post‐treatment. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.13, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.18, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mean higher‐order aberrations (HOAs) microns post‐treatment, measured by machine with wavefront sensor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.07, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Wavefront‐guided LASIK vs Wavefront‐guided PRK</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012687.pub2/references#CD012687-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012687.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012687-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012687-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012687-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012687-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012687-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012687\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012687\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012687\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012687\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012687\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012687.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012687.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012687.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012687.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012687.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719891642"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012687.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719891646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012687.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df3c9c94d937f',t:'MTc0MDcxOTg5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 